Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

DNTH

Dianthus Therapeutics Inc

Feb 13 • 04:00PM ET

47.40

-0.08 -0.17 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX REGN BIIB GILD AMGN MRNA BMY LLY PFE ABBV

| Held by: VTI XBI IWM VXF IWN SCHA VTWO AVSC IWC DFAS

Index	RUT	P/E	-	EPS (ttm)	-3.49	Insider Own	20.03%	Shs Outstand	42.85M	Perf Week	-6.60%
Market Cap	2.05B	Forward P/E	-	EPS next Y	-3.71	Insider Trans	-2.66%	Shs Float	34.57M	Perf Month	2.40%
Enterprise Value	1.65B	PEG	-	EPS next Q	-1.07	Inst Own	99.16%	Short Float	24.01%	Perf Quarter	22.42%
Income	-126.34M	P/S	665.19	EPS this Y	-44.08%	Inst Trans	5.23%	Short Ratio	10.35	Perf Half Y	134.07%
Sales	3.08M	P/B	3.72	EPS next Y	-1.08%	ROA	-27.12%	Short Interest	8.30M	Perf YTD	15.02%
Book/sh	12.75	P/C	5.09	EPS next 5Y	-18.87%	ROE	-28.57%	52W High	57.50 -17.57%	Perf Year	96.44%
Cash/sh	9.31	P/FCF	-	EPS past 3/5Y	50.25% 40.14%	ROIC	-23.08%	52W Low	13.36 254.66%	Perf 3Y	248.53%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	86.71%	Volatility	6.43% 6.80%	Perf 5Y	-70.23%
Dividend TTM	-	EV/Sales	534.88	EPS Y/Y TTM	-39.78%	Oper. Margin	-4558.41%	ATR (14)	3.15	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	17.35	Sales Y/Y TTM	-42.64%	Profit Margin	-4104.78%	RSI (14)	48.47	Recom	1.13
Dividend Gr. 3/5Y	- -	Current Ratio	17.35	EPS Q/Q	-32.30%	SMA20	-5.39%	Beta	1.59	Target Price	75.25
Payout	-	Debt/Eq	0.00	Sales Q/Q	-81.77%	SMA50	5.10%	Rel Volume	0.53	Prev Close	47.48
Employees	78	LT Debt/Eq	0.00	Earnings	Nov 05 AMC	SMA200	50.26%	Avg Volume	801.86K	Price	47.40
IPO	Jun 21, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	-11.82% -31.25%	Trades		Volume	424,302	Change	-0.17%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-14-25	Initiated	Truist	Buy	$56
Jul-02-25	Initiated	William Blair	Outperform
Dec-20-24	Initiated	TD Cowen	Buy
Oct-03-24	Initiated	Oppenheimer	Outperform	$48
Jul-26-24	Initiated	Robert W. Baird	Outperform	$58
Jun-27-24	Initiated	Cantor Fitzgerald	Overweight
May-16-24	Initiated	H.C. Wainwright	Buy	$40
Feb-15-24	Initiated	Stifel	Buy	$44
Dec-26-23	Initiated	Jefferies	Buy	$22
Nov-22-23	Initiated	Wedbush	Outperform	$23
Oct-30-23	Initiated	Guggenheim	Buy	$45
Sep-28-23	Initiated	Raymond James	Outperform	$24
Aug-25-22	Downgrade	Goldman	Buy → Neutral	$2
Jan-06-22	Upgrade	Goldman	Neutral → Buy	$7 → $8
Aug-20-21	Resumed	Goldman	Neutral	$7
Aug-03-21	Downgrade	JP Morgan	Overweight → Neutral	$16 → $7
Jul-22-21	Reiterated	B. Riley Securities	Buy	$21 → $19
Jun-29-21	Initiated	Cantor Fitzgerald	Overweight	$20
Jun-15-21	Initiated	BTIG Research	Buy	$20
May-18-21	Initiated	B. Riley Securities	Buy	$21

Show Previous Ratings

Feb-13-26 10:27AM	Dianthus Therapeutics Conference: DNTH Eyes Q2 2026 CIDP Phase 3 Interim Readout, Expands Pipeline Plans (MarketBeat)
Feb-05-26 07:00AM	Dianthus Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire)
Jan-23-26 05:42AM	Dianthus Therapeutics, Inc. (DNTH) Moves 9.9% Higher: Will This Strength Last? (Zacks)
Jan-05-26 07:00AM	Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -7.03%
Dec-23-25 06:00AM	Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE) (GlobeNewswire)
06:35PM	Loading…
Dec-05-25 06:35PM	Ashland, Bitdeer, and More Stocks See Action From Activist Investors (Barrons.com)
Nov-24-25 07:00AM	Dianthus Therapeutics To Participate in the 8th Annual Evercore Healthcare Conference (GlobeNewswire) +5.38%
Nov-05-25 05:35PM	Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Lags Revenue Estimates (Zacks) +8.00%
04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results (GlobeNewswire)
Nov-04-25 05:10PM	Day One Biopharmaceuticals, Inc. (DAWN) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Dianthus Therapeutics to Participate in Four Investor Conferences During November (GlobeNewswire)
Oct-30-25 10:00AM	Dianthus Therapeutics, Inc. (DNTH) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-29-25 03:30PM	Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting (GlobeNewswire)
Oct-16-25 07:00AM	Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases (GlobeNewswire)
Oct-02-25 08:00AM	Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting (GlobeNewswire) -5.14%
11:50AM	Loading…
Sep-30-25 11:50AM	Clear Street Initiates Buy on Dianthus Therapeutics, Inc. (DNTH) With $100 Price Target (Insider Monkey)
Sep-19-25 03:26PM	Dianthus, Opendoor, and More Stocks See Action From Activist Investors (Barrons.com) -5.45%
Sep-11-25 04:07PM	Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Sep-09-25 10:35PM	Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering (GlobeNewswire) +11.86% +6.55%
10:57AM	Dianthus Therapeutics (DNTH) Hits New High as Drug Trial Sparks Optimism for Blockbuster Potential (Insider Monkey)
07:15AM	Dianthus to take gMG mAb to Phase III after mid-stage win (Clinical Trials Arena)
Sep-08-25 04:00PM	Dianthus Therapeutics, Inc. Announces Proposed $150 Million Underwritten Public Offering (GlobeNewswire) +20.00%
02:45PM	Dianthus Therapeutics Stock Earns RS Rating Upgrade (Investor's Business Daily)
01:21PM	Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again (Investor's Business Daily)
07:00AM	Dianthus Therapeutics Announces Positive Data for Claseprubart (DNTH103) from the Phase 2 MaGic Trial in Generalized Myasthenia Gravis, Supporting Its Potential Best-In-Class Profile (GlobeNewswire)
Sep-07-25 06:25PM	Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis (GlobeNewswire)
Aug-13-25 04:04PM	The Oncology Institute Announces Changes to Board of Directors (GlobeNewswire)
Aug-07-25 05:20PM	Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -6.08%
04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results (GlobeNewswire)
10:00AM	Earnings Preview: Dianthus Therapeutics, Inc. (DNTH) Q2 Earnings Expected to Decline (Zacks)
06:45PM	Loading…
Aug-06-25 06:45PM	Seer, Inc. (SEER) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Jun-21-25 03:50PM	Stifel Reaffirms Buy on Dianthus Therapeutics, Inc. (DNTH) with 186% Upside (Insider Monkey)
May-29-25 07:00AM	Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-22-25 04:10PM	Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors (GlobeNewswire)
May-12-25 05:10PM	Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -6.18%
04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results (GlobeNewswire)
May-07-25 05:35PM	Emergent Biosolutions (EBS) Q1 Earnings Top Estimates (Zacks)
May-05-25 07:00AM	Dianthus Therapeutics Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expected in September (GlobeNewswire)
Apr-29-25 07:00AM	Dianthus Therapeutics to Participate in Two Upcoming Investor Events (GlobeNewswire)
Apr-23-25 02:53PM	Dianthus Therapeutics: Complement Therapy Developer With Long Road Ahead (Seeking Alpha)
Apr-03-25 10:03AM	Dianthus Therapeutics, Inc. (DNTH) Soars 6.1%: Is Further Upside Left in the Stock? (Zacks)
Mar-24-25 09:57AM	Alnylam (ALNY) Surges 11.8%: Is This an Indication of Further Gains? (Zacks)
Mar-11-25 04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results (GlobeNewswire) -6.33%
Mar-05-25 07:00AM	Dianthus Therapeutics Strengthens Strategic Commercial Leadership With Appointment of John C. King as Chief Commercial Officer and Welcomes Sujay Kango, A Seasoned Commercial Leader, to Board of Directors (GlobeNewswire) +14.60%
Feb-26-25 07:00AM	Dianthus Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire) -6.32%
Jan-30-25 07:00AM	Dianthus Therapeutics to Webcast Presentations at Two Investor Conferences (GlobeNewswire)
Jan-08-25 07:00AM	Dianthus Therapeutics to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-07-24 04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results (GlobeNewswire)
Nov-04-24 07:00AM	Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences (GlobeNewswire)
Oct-15-24 07:00AM	Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting (GlobeNewswire) +8.30%
Sep-04-24 07:00AM	Dianthus Therapeutics to Participate in Three Healthcare Investor Conferences in September (GlobeNewswire)
Aug-08-24 04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results (GlobeNewswire)
Jul-08-24 11:06AM	Dianthus (DNTH) Gains 18% in the Past Month: Here's Why (Zacks) +11.93%
Jun-28-24 11:30AM	Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN) (GlobeNewswire)
Jun-12-24 07:00AM	Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN) (GlobeNewswire) +5.01%
May-30-24 04:30PM	Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire) -6.59%
May-09-24 10:56PM	DNTH Stock Earnings: Dianthus Therapeutics Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results (GlobeNewswire)
May-08-24 04:30PM	Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference (GlobeNewswire)
May-03-24 04:30PM	Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.46% -7.29%
Apr-11-24 07:30AM	Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting (GlobeNewswire) +9.11%
Apr-05-24 04:30PM	Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.02%
Mar-21-24 10:54PM	DNTH Stock Earnings: Dianthus Therapeutics Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) +14.32%
04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results (GlobeNewswire)
Mar-07-24 04:30PM	Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-26-24 07:00AM	Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG) (GlobeNewswire)
Feb-23-24 08:00AM	Dianthus Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Jan-31-24 04:05PM	Dianthus Therapeutics to Participate at the Guggenheim 6th Annual Biotechnology Conference (GlobeNewswire) +9.05%
Jan-22-24 07:30AM	Dianthus Therapeutics Announces $230 Million Private Placement (GlobeNewswire) +37.24%
Jan-02-24 08:30AM	Dianthus Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +10.10%
Dec-14-23 07:04AM	DNTH Stock Earnings: Dianthus Therapeutics Reported Results for Q3 2023 (InvestorPlace)
Nov-29-23 04:05PM	Dianthus Therapeutics Enhances Leadership Team with Appointment of Jeffrey Stavenhagen, Ph.D., as Chief Scientific Officer (GlobeNewswire)
Nov-09-23 04:05PM	Dianthus Therapeutics Highlights Recent Business Achievements and Third Quarter 2023 Financial Results (GlobeNewswire)
Sep-14-23 05:04PM	Insider Buying: Fairmount Funds Management LLC Acquires 24,254 Shares of Dianthus Therapeutics Inc (GuruFocus.com)
Aug-14-23 01:35PM	CEO of shuttered biotech Magenta Therapeutics makes leap to Flagship startup (American City Business Journals)
May-03-23 04:19PM	Magenta Sets Up Dianthus Merger After Stopping Blood Cancer Trial Due To Patient Death (Benzinga) -14.29%
07:00AM	Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement (GlobeNewswire)
Mar-31-23 04:10PM	Magenta Therapeutics Adopts Limited Duration Stockholder Rights Plan (GlobeNewswire)
06:09AM	The Zacks Analyst Blog Highlights Blue Bird, Comfort Systems, Salesforce, Deckers Outdoor and Magenta Therapeutics (Zacks)
Mar-27-23 10:20AM	Is Magenta Therapeutics (NASDAQ:MGTA) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Feb-09-23 01:24PM	On eve of shutdown, Cambridge biotech loses 84% of staff, including 5 execs (American City Business Journals)
10:13AM	Magenta's CEO Leaves After Patient Death Halts Trials, Shuttering Concerns Looms (Benzinga)
Feb-03-23 01:35PM	Magenta Therapeutics to shut down after patient death (American City Business Journals) +51.66%
Feb-02-23 04:05PM	Magenta Therapeutics to Explore Strategic Alternatives (GlobeNewswire)
05:58AM	The Petri Dish: Departed White House adviser returns to the Broad (American City Business Journals)
Jan-25-23 04:05PM	Magenta Therapeutics Voluntarily Pauses the MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial to Investigate Drug Safety (GlobeNewswire) +6.89% -11.09%
Dec-21-22 07:39AM	Magenta (MGTA) Down on Pipeline Update for Leukemia Drug (Zacks) -7.64%
Dec-20-22 11:20AM	Magenta Therapeutics Shares Crashes As Dose-Limiting Toxicities Observed In Lead Blood Cancer Study (Benzinga) -52.71%
09:00AM	Magenta Therapeutics Provides Update for MGTA-117 Phase 1/2 Dose Escalation Clinical Trial (GlobeNewswire)
Dec-13-22 05:56AM	Magenta Therapeutics Shares Surge After Encouraging Data From Blood Cancer Candidate At ASH Meeting (Benzinga) -7.83%
Dec-12-22 04:30PM	Magenta Therapeutics Presents Positive MGTA-117 Clinical Data at the American Society of Hematology (ASH) Annual Meeting and Provides Program Updates (GlobeNewswire)
08:00AM	Magenta Therapeutics to Host Conference Call and Webcast on Tuesday, December 13, 2022, to Review MGTA-117 Clinical Data from Ongoing Phase 1/2 Clinical Trial (GlobeNewswire)
Nov-03-22 09:01AM	Magenta Therapeutics to Present Data at the 2022 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
09:01AM	Magenta Therapeutics Reports Third Quarter Financial Results and Recent Program Highlights (GlobeNewswire)
Nov-01-22 08:00AM	Magenta Therapeutics to Participate in the Credit Suisse 31st Annual Healthcare Conference (GlobeNewswire)
Oct-17-22 12:16PM	We Think Magenta Therapeutics (NASDAQ:MGTA) Needs To Drive Business Growth Carefully (Simply Wall St.)
Sep-23-22 09:15AM	Australian Billionaire Kerr Neilson is Selling These 15 Stocks (Insider Monkey)
Aug-17-22 08:00AM	Magenta Therapeutics Appoints Michael Vasconcelles, M.D. to the Board of Directors (GlobeNewswire)
Aug-04-22 08:00AM	Magenta Therapeutics Reports Second Quarter Financial Results and Recent Program Highlights (GlobeNewswire)
Aug-02-22 08:00AM	Magenta Therapeutics to Participate in Panel Discussion at the 2022 Wedbush PacGrow Healthcare Conference (GlobeNewswire)

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company was founded on June 17, 2015 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Savitz Ryan	CFO & CBO	Dec 04 '25	Option Exercise	8.44	20,000	168,800	20,000	Dec 05 08:00 PM
Savitz Ryan	CFO & CBO	Dec 04 '25	Sale	45.18	20,000	903,600	0	Dec 05 08:00 PM
RYAN SAVITZ	Officer	Dec 04 '25	Proposed Sale	43.97	20,000	879,400		Dec 04 04:42 PM
Randhawa Simrat	EVP, Head of R&D	Nov 14 '25	Option Exercise	20.42	109,031	2,226,263	113,031	Nov 14 09:00 PM
Randhawa Simrat	EVP, Head of R&D	Nov 13 '25	Option Exercise	8.82	87,507	771,873	91,507	Nov 14 09:00 PM
Randhawa Simrat	EVP, Head of R&D	Nov 14 '25	Sale	38.14	109,031	4,158,442	4,000	Nov 14 09:00 PM
Randhawa Simrat	EVP, Head of R&D	Nov 13 '25	Sale	36.81	87,507	3,221,445	4,000	Nov 14 09:00 PM
SIMRAT RANDHAWA	Officer	Nov 13 '25	Proposed Sale	38.72	196,538	7,609,951		Nov 13 04:23 PM
Savitz Ryan	CFO & CBO	Sep 09 '25	Option Exercise	8.44	20,000	168,800	20,000	Sep 11 05:20 PM
Savitz Ryan	CFO & CBO	Sep 09 '25	Sale	35.00	20,000	700,000	0	Sep 11 05:20 PM
RYAN SAVITZ	Officer	Sep 09 '25	Proposed Sale	31.80	20,000	636,000		Sep 09 04:27 PM

Open in Screener

RVMD

Revolution Medicines Inc

Feb 13 • 04:00PM ET

96.31

-1.02 -1.05 %

Healthcare • Biotechnology • USA • NASD

RVMD Revolution Medicines Inc daily Stock Chart

Peers: AMGN GILD VRTX BMY MRNA PFE REGN ILMN BIIB EXEL

| Held by: VTI VB VBK VXF XBI IBB SCHA IWR SCHM IWD

Index	-	P/E	-	EPS (ttm)	-5.18	Insider Own	14.49%	Shs Outstand	189.71M	Perf Week	-1.21%
Market Cap	18.62B	Forward P/E	-	EPS next Y	-6.60	Insider Trans	-1.66%	Shs Float	165.30M	Perf Month	-20.55%
Enterprise Value	16.85B	PEG	-	EPS next Q	-1.58	Inst Own	91.44%	Short Float	7.91%	Perf Quarter	46.30%
Income	-960.98M	P/S	-	EPS this Y	-57.14%	Inst Trans	2.99%	Short Ratio	3.88	Perf Half Y	167.38%
Sales	0.00M	P/B	11.44	EPS next Y	-17.38%	ROA	-47.87%	Short Interest	13.07M	Perf YTD	20.92%
Book/sh	8.42	P/C	9.64	EPS next 5Y	-16.80%	ROE	-60.76%	52W High	124.49 -22.64%	Perf Year	133.08%
Cash/sh	9.99	P/FCF	-	EPS past 3/5Y	-11.66% -27.80%	ROIC	-55.26%	52W Low	29.17 230.17%	Perf 3Y	277.09%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	2.87% 3.53%	Perf 5Y	93.47%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-44.24%	Oper. Margin	-	ATR (14)	4.23	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.05	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	46.32	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	8.05	EPS Q/Q	-72.19%	SMA20	-5.96%	Beta	1.00	Target Price	121.94
Payout	-	Debt/Eq	0.10	Sales Q/Q	-	SMA50	3.00%	Rel Volume	0.47	Prev Close	97.33
Employees	534	LT Debt/Eq	0.09	Earnings	Nov 05 AMC	SMA200	68.02%	Avg Volume	3.37M	Price	96.31
IPO	Feb 13, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-13.29% -100.00%	Trades		Volume	1,569,801	Change	-1.05%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-18-25	Initiated	Wolfe Research	Outperform	$75
Nov-03-25	Initiated	RBC Capital Mkts	Outperform	$77
Oct-21-25	Initiated	Mizuho	Outperform	$90
Oct-16-25	Resumed	Stifel	Buy	$85
Sep-12-25	Resumed	Raymond James	Strong Buy	$72
Sep-05-25	Initiated	Truist	Buy	$99
Aug-19-25	Initiated	Piper Sandler	Overweight	$75
Aug-15-25	Initiated	Wells Fargo	Overweight	$67
Jul-15-25	Initiated	Goldman	Buy	$65
Jul-16-24	Reiterated	Needham	Buy	$46 → $62
Jul-12-24	Initiated	Barclays	Overweight	$52
Jul-08-24	Initiated	Jefferies	Buy	$63
Apr-12-24	Reiterated	Needham	Buy	$36 → $46
Apr-10-24	Upgrade	Raymond James	Outperform → Strong Buy	$36 → $48
Mar-11-24	Initiated	Piper Sandler	Overweight	$43
Jan-05-24	Upgrade	BofA Securities	Neutral → Buy	$31 → $34
Jan-04-24	Initiated	Wedbush	Outperform	$41
Nov-16-23	Initiated	Raymond James	Outperform	$30
Feb-28-23	Upgrade	JP Morgan	Neutral → Overweight	$32 → $38
Dec-14-22	Initiated	Needham	Buy	$31

Show Previous Ratings

Today 02:02PM	Tango Therapeutics CEO Teases Pivotal Vopimetostat Trial, RAS Combo Data at Guggenheim Chat (MarketBeat)
Feb-14-26 10:02PM	Revolution Medicines Conference: CEO Details Daraxonrasib Phase III Timeline, First-Line PDAC Push (MarketBeat)
Feb-13-26 02:07PM	Erasca Touts Early ERAS-0015 Responses, Potency Edge in Guggenheim Fireside Chat (MarketBeat)
Feb-04-26 04:05PM	Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026 (GlobeNewswire)
Jan-29-26 08:00AM	Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor (GlobeNewswire)
10:53AM	Loading…
Jan-27-26 10:53AM	RVMD Stock Tumbles as MRK Reportedly Withdraws Buyout Offer (Zacks)
06:23AM	Stock Index Futures Gain on Tech Boost, FOMC Meeting and Earnings in Focus (Barchart)
05:02AM	Revolution Medicines (RVMD) Dives 16.9% as Merck Withdraws Takeover Plan (Insider Monkey)
03:39AM	Stock Market Today: Nasdaq Futures Rise Ahead of Earnings; Yen Weakens (The Wall Street Journal)
Jan-26-26 07:36PM	Why Revolution Medicines Stock Plummeted by Almost 17% Today (Motley Fool) -16.87%
04:56PM	Stocks to Watch Monday Recap: CoreWeave, IonQ, USA Rare Earth, RevMed (The Wall Street Journal)
04:32PM	Stocks Close Higher Ahead of Heavy Earnings Week and FOMC Meeting (Barchart)
01:48PM	Stocks to Watch Monday: CoreWeave, IonQ, USA Rare Earth, RevMed (The Wall Street Journal)
01:26PM	Natural Gas Rallies 30%, Silver Jumps 13% To $116: What's Moving Markets Monday? (Benzinga)
01:12PM	Stock Market Today: Trump's Medicare announcement slams health insurers (TheStreet)
12:47PM	Loading…
12:47PM	Merck Ends Acquisition Talks With Revolution Medicines After Valuation Dispute (GuruFocus.com)
11:41AM	Stocks See Support Ahead of Heavy Earnings Week and FOMC Meeting (Barchart)
09:44AM	Stocks to Watch Monday: CoreWeave, American Airlines, IonQ, Enphase (The Wall Street Journal)
09:09AM	Revolution Medicines stock falls after Merck reportedly ends acquisition pursuit (Investing.com)
07:52AM	Why Is Cancer Drug Developer Erasca Stock Trading Lower Monday? (Benzinga)
07:19AM	MSD ends takeover talks with Revolution Medicines (Pharmaceutical Technology)
06:22AM	Stocks Set for Muted Open After Trumps Tariff Threats, Big Tech Earnings and Fed Meeting in Focus (Barchart)
06:01AM	Revolution Medicines Stock Sinks After Merck Deal Talks Collapse (Benzinga)
Jan-25-26 02:43PM	Merck No Longer In Talks With Revolution Medicines: WSJ (Barrons.com)
02:30PM	Merck No Longer in Talks to Buy Revolution Medicines (The Wall Street Journal)
Jan-22-26 02:31PM	Biotech stocks are among today's winners (MarketWatch)
09:10AM	Jim Cramer Highlights "Takeover Interest" in Revolution Medicines (Insider Monkey)
Jan-16-26 01:43AM	On biotechs biggest stage, renewed excitement gets a stress test (BioPharma Dive)
Jan-13-26 05:59AM	JPM26: Day 1 drug prices and policy changes drive the agenda (Pharmaceutical Technology)
Jan-12-26 08:51AM	AbbVie Down 3% in a Month: Why Holding the Stock Still Makes Sense (Zacks)
07:54AM	Loading…
07:54AM	JPM26: Revolution Medicines in spotlight as industry gears up for dealmaking spree (Pharmaceutical Technology)
Jan-11-26 08:01AM	Sandisk, Bloom Energy, And Oklo Are Among the Top 10 Large-Cap Gainers Last Week (Jan. 5-Jan. 9): Are the Others in Your Portfolio? (Benzinga)
Jan-09-26 08:16PM	Why Revolution Medicines Stock Surged by 11% Today (Motley Fool) +10.48%
04:46PM	Deal Dispatch: Saks Faces A Luxury Liquidity Crisis, Soho House Gets Quiet (Benzinga)
04:43PM	These Stocks Moved the Most Today: Oklo, Vistra, Opendoor, Intel, GM, Revolution Medicines, Tilray, and More (Barrons.com)
04:38PM	S&P 500 Rallies to a New Record High on US Economic Optimism (Barchart)
03:18PM	These Stocks Are Moving the Most Today: Oklo, Vistra, Opendoor, Intel, GM, Revolution Medicines, Tilray, and More (Barrons.com)
02:58PM	Merck in Talks to Buy Revolution Medicines for Around $30 Billion (The Wall Street Journal)
12:03PM	Merck in Talks to Buy Revolution Medicines Per Financial Times Report (Zacks)
11:19AM	Healthcare dealmakers head to San Francisco hoping for megamergers in 2026 (Reuters)
09:54AM	Revolution Medicines Stock Jumps. Takeover Buzz Grows, Another Suitor Emerges. (Barrons.com)
06:20AM	December Jobs Report Miss Forecasts While Unemployment Defies Expectations (Barchart)
05:56AM	These Stocks Are Moving the Most Today: Opendoor, Rocket Cos., GM, Apple, Glencore, Revolution Medicines, Tilray, and More (Barrons.com)
05:54AM	Revolution Medicines Stock Soars. Takeover Buzz Grows, Another Suitor Emerges. (Barrons.com)
01:52AM	Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal - Stock Soars Overnight (Benzinga)
Jan-08-26 07:51PM	Merck in talks to buy cancer drugmaker Revolution Medicines for up to $32bn (Financial Times)
04:25PM	Revolution Medicines stock rises on Merck acquisition talks (Investing.com)
03:58PM	Merck in talks to buy biotech Revolution Medicines, FT reports (Reuters)
01:41PM	AbbVie Stock Drops After Guidance Update, Wolfe Downgrade And Deal Denial (Benzinga)
01:21PM	What's Going With Cancer Biotech Erasca Stock On Thursday? (Benzinga)
11:23AM	Stock Indexes Mixed on Big Tech Weakness and Higher Bond Yields (Barchart)
09:11AM	RVMD Stock Hits a Record High on Rumored Takeover Interest (Zacks)
08:38AM	These Stocks Are Moving the Most Today: Lockheed, Northrop, Alphabet, Revolution Medicines, AbbVie, Costco, and More (Barrons.com)
08:00AM	Revolution Medicines Announces FDA Breakthrough Therapy Designation for Zoldonrasib (GlobeNewswire)
07:38AM	AbbVie Denies It's in Talks to Buy Revolution Medicines. Both Stocks Are Falling. (Barrons.com)
03:13AM	Why Revolution Medicines Shares Are Sliding After Hours On Wednesday (Benzinga)
Jan-07-26 09:18PM	Revolution Medicines (RVMD) Hits All-Time High on Buyout Buzz; Buyer Denies Talks (Insider Monkey) +28.63%
05:44PM	Revolution Medicines Draws Takeover Interest (The Wall Street Journal)
03:33PM	Revolution Medicines stock surges over 20% on potential AbbVie acquisition (Investing.com)
02:48PM	AbbVie Near Deal for Revolution Medicines (The Wall Street Journal)
Jan-05-26 04:05PM	Revolution Medicines to Present at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-18-25 08:00AM	Revolution Medicines Announces First Patient Randomized in the RASolute 304 Clinical Trial of Daraxonrasib in Resectable Pancreatic Ductal Adenocarcinoma Following Adjuvant Chemotherapy (GlobeNewswire)
Dec-05-25 11:30AM	Revolution Medicines (RVMD) Up 27.9% Since Last Earnings Report: Can It Continue? (Zacks)
Dec-04-25 11:00AM	This Oncology Stock Just Hit New All-Time Highs (Barchart)
Nov-06-25 01:59PM	Revolution Medicines Posts Wider-Than-Expected Loss in Q3, Sales Nil (Zacks)
12:05AM	Revolution Medicines Inc (RVMD) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Nov-05-25 04:02PM	Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress (GlobeNewswire)
Nov-04-25 04:05PM	Revolution Medicines to Participate in November 2025 Investor Conferences (GlobeNewswire)
07:24AM	Revolution Medicines Inc (RVMD) Q3 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Nov-03-25 09:42AM	Boeing upgraded, Charter downgraded: Wall Street's top analyst calls (The Fly)
Oct-29-25 04:05PM	Revolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025 (GlobeNewswire)
Oct-27-25 08:00AM	Revolution Medicines' RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer (GlobeNewswire) +6.44%
Oct-22-25 12:12PM	Revolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C Inhibitor (GlobeNewswire)
Oct-20-25 08:25AM	FDA Grants First CNPV Vouchers, Igniting Rally in Biotech Stocks (GuruFocus.com)
Oct-19-25 03:21AM	Jim Cramer Says Revolution Medicines "Is a Speculative Situation" (Insider Monkey)
Oct-17-25 10:17AM	The FDA Just Granted Its Speediest Review Ever. Disc Medicine, Others Fly. (Investor's Business Daily) +8.90%
Oct-16-25 08:00PM	Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner's National Priority Voucher Pilot Program (GlobeNewswire)
Oct-02-25 09:45AM	Revolution Medicines, Inc. (RVMD) Insider Sells Shares (Insider Monkey)
Sep-29-25 09:00AM	Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer (GlobeNewswire)
Sep-25-25 06:15AM	These 2 Stocks Could Be Prime Takeover Targets, According to Analysts (TipRanks)
Sep-12-25 09:00AM	Morning Movers: Kroger rises following second quarter results (TipRanks)
Sep-11-25 07:42AM	Revolutions daraxonrasib moves to Phase III after PDAC hat-trick (Clinical Trials Arena) +14.31%
Sep-10-25 04:02PM	Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma (GlobeNewswire)
Sep-02-25 01:34AM	Oppenheimer Reaffirms Outperform on Revolution Medicines (RVMD) Amid RAS Therapy Progress (Insider Monkey)
Aug-28-25 11:49PM	Here's What the Wall Street Thinks About Revolution Medicines (RVMD) (Insider Monkey)
Aug-22-25 11:57PM	Piper Sandler Initiates Coverage of Revolution Medicines (RVMD) with an Overweight Rating (Insider Monkey)
Aug-15-25 09:32AM	Target downgraded, Salesforce upgraded: Wall Street's top analyst calls (The Fly)
Aug-13-25 03:11PM	Revolution Medicines Receives FDA Breakthrough Therapy Designation for Elironrasib for Lung Cancer (Insider Monkey)
Aug-06-25 04:02PM	Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress (GlobeNewswire)
07:00AM	Royalty Pharma Reports Second Quarter 2025 Results (GlobeNewswire)
Aug-05-25 09:28AM	What To Expect From Revolution Medicines Inc (RVMD) Q2 2025 Earnings (GuruFocus.com)
Jul-30-25 04:05PM	Revolution Medicines to Report Financial Results for Second Quarter 2025 After Market Close on August 6, 2025 (GlobeNewswire)
Jul-28-25 09:55AM	Wall Street Analysts Believe Revolution Medicines (RVMD) Could Rally 90.58%: Here's is How to Trade (Zacks)
Jul-24-25 04:00PM	Revolution Medicines Announces Publication of a Peer-Reviewed Research Paper in Science on the Discovery and Development of Zoldonrasib, a RAS(ON) G12D-Selective Inhibitor (GlobeNewswire)
04:00AM	iOnctura Strengthens Medical and Commercialization Expertise with Two Non-Executive Board Appointments (PR Newswire)
Jul-23-25 08:00AM	Revolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib (GlobeNewswire)
Jul-16-25 09:39AM	Revolution Medicines (RVMD) Gets Initiated With a New Buy Rating at Goldman Sachs (Insider Monkey)
Jul-09-25 08:00AM	Revolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic's AI Discovery Tools to Pursue New Drug Candidates (GlobeNewswire) +5.71%
12:55AM	Revolution Medicines' Daraxonrasib Granted FDA Breakthrough Therapy Designation for Pancreatic Cancer with KRAS G12 Mutations (Insider Monkey)
Jul-06-25 04:00AM	Revolution Medicines, Summit Therapeutics Partner on RAS Inhibitor/Ivonescimab Combinations for Solid Tumors (Insider Monkey)

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GOLDSMITH MARK A	See Remarks	Feb 06 '26	Option Exercise	0.54	24,010	12,965	256,479	Feb 10 05:30 PM
Cislini Jeff	General Counsel	Jan 21 '26	Sale	115.60	908	104,965	46,976	Jan 23 04:31 PM
JEFFREY TODD CISLINI	Officer	Jan 21 '26	Proposed Sale	116.22	908	105,528		Jan 21 04:23 PM
Horn Margaret A	Chief Operating Officer	Jan 07 '26	Option Exercise	38.47	75,000	2,885,286	216,053	Jan 09 04:20 PM
Horn Margaret A	Chief Operating Officer	Jan 07 '26	Sale	100.56	75,000	7,542,023	141,053	Jan 09 04:20 PM
Anders Jack	Chief Financial Officer	Jan 07 '26	Option Exercise	42.45	10,000	424,500	118,065	Jan 09 04:20 PM
Anders Jack	Chief Financial Officer	Jan 07 '26	Sale	98.00	10,000	980,000	108,065	Jan 09 04:20 PM
MARGARET A HORN	Officer	Jan 07 '26	Proposed Sale	79.85	75,000	5,988,750		Jan 07 04:23 PM
JACK LEE ANDERS	Officer	Jan 07 '26	Proposed Sale	79.85	10,000	798,500		Jan 07 04:22 PM
Cislini Jeff	General Counsel	Dec 16 '25	Sale	76.82	2,688	206,484	47,884	Dec 18 04:17 PM
GOLDSMITH MARK A	See Remarks	Dec 16 '25	Sale	76.82	15,394	1,182,526	232,469	Dec 18 04:17 PM
Kelsey Stephen Michael	See Remarks	Dec 16 '25	Sale	76.82	5,447	418,423	278,600	Dec 18 04:16 PM
Horn Margaret A	Chief Operating Officer	Dec 16 '25	Sale	76.82	4,847	372,333	141,053	Dec 18 04:16 PM
Anders Jack	Chief Financial Officer	Dec 16 '25	Sale	77.09	3,104	239,289	108,065	Dec 18 04:15 PM
GOLDSMITH MARK A	Officer	Dec 15 '25	Proposed Sale	77.81	14,964	1,164,349		Dec 12 09:03 PM
Kelsey Stephen Michael	Officer	Dec 15 '25	Proposed Sale	77.81	5,296	412,082		Dec 12 09:00 PM
Cislini Jeff	Officer	Dec 15 '25	Proposed Sale	77.81	2,614	203,395		Dec 12 08:59 PM
Anders Jack	Officer	Dec 15 '25	Proposed Sale	77.81	3,017	234,753		Dec 12 08:57 PM
Horn Margaret A	Officer	Dec 15 '25	Proposed Sale	77.81	4,711	366,563		Dec 12 08:55 PM
Anders Jack	Chief Financial Officer	Nov 25 '25	Option Exercise	17.00	5,418	92,106	116,412	Nov 26 04:16 PM
Anders Jack	Chief Financial Officer	Nov 25 '25	Sale	74.00	5,418	400,932	110,994	Nov 26 04:16 PM
GOLDSMITH MARK A	See Remarks	Nov 25 '25	Option Exercise	4.09	60,000	245,400	307,863	Nov 26 04:15 PM
GOLDSMITH MARK A	See Remarks	Nov 25 '25	Sale	75.08	60,000	4,504,962	247,863	Nov 26 04:15 PM
GOLDSMITH MARK A	See Remarks	Nov 25 '25	Sale	75.00	6,000	450,000	67,424	Nov 26 04:15 PM
J H GOLDSMITH & M A GOLDSMITHC	Director	Nov 25 '25	Proposed Sale	73.66	3,000	220,980		Nov 25 04:29 PM
THE REBECCA GOLDSMITH REVOCABL	Director	Nov 25 '25	Proposed Sale	73.66	3,000	220,980		Nov 25 04:29 PM
MARK A GOLDSMITH	Director	Nov 25 '25	Proposed Sale	73.66	60,000	4,419,600		Nov 25 04:28 PM
JACK LEE ANDERS	Officer	Nov 25 '25	Proposed Sale	73.66	5,418	399,090		Nov 25 04:25 PM
GOLDSMITH MARK A	See Remarks	Nov 18 '25	Option Exercise	4.09	20,000	81,800	267,863	Nov 20 04:23 PM
GOLDSMITH MARK A	See Remarks	Nov 18 '25	Sale	70.38	20,000	1,407,586	247,863	Nov 20 04:23 PM
Cislini Jeff	General Counsel	Nov 18 '25	Option Exercise	42.45	13,388	568,321	63,813	Nov 20 04:23 PM
Cislini Jeff	General Counsel	Nov 18 '25	Sale	70.14	13,388	939,008	50,425	Nov 20 04:23 PM
MARK A GOLDSMITH	Director	Nov 18 '25	Proposed Sale	69.14	20,000	1,382,800		Nov 18 04:23 PM
JEFFREY TODD CISLINI	Officer	Nov 18 '25	Proposed Sale	69.14	13,388	925,646		Nov 18 04:23 PM
GOLDSMITH MARK A	See Remarks	Nov 12 '25	Option Exercise	4.09	20,000	81,800	267,863	Nov 14 08:45 PM
GOLDSMITH MARK A	See Remarks	Nov 12 '25	Sale	65.07	20,000	1,301,410	247,863	Nov 14 08:45 PM
Anders Jack	Chief Financial Officer	Nov 11 '25	Option Exercise	17.00	10,000	170,000	120,994	Nov 13 04:20 PM
Anders Jack	Chief Financial Officer	Nov 11 '25	Sale	64.00	10,000	640,000	110,994	Nov 13 04:20 PM
GOLDSMITH MARK A	See Remarks	Nov 07 '25	Option Exercise	1.47	30,000	44,057	377,863	Nov 12 08:12 PM
GOLDSMITH MARK A	See Remarks	Nov 07 '25	Sale	60.31	30,000	1,809,306	347,863	Nov 12 08:12 PM
MARK A GOLDSMITH	Director	Nov 12 '25	Proposed Sale	64.08	20,000	1,281,600		Nov 12 04:40 PM
JACK LEE ANDERS	Officer	Nov 11 '25	Proposed Sale	62.73	10,000	627,300		Nov 12 07:04 AM
MARK A GOLDSMITH	Director	Nov 07 '25	Proposed Sale	61.38	30,000	1,841,400		Nov 07 04:38 PM
MARK A GOLDSMITH	Director	Oct 17 '25	Proposed Sale	49.68	10,000	496,800		Oct 17 04:18 PM
JEFFREY TODD CISLINI	Officer	Oct 17 '25	Proposed Sale	49.68	12,000	596,160		Oct 17 04:17 PM
MARK A GOLDSMITH	Director	Oct 16 '25	Proposed Sale	49.56	10,000	495,600		Oct 16 04:21 PM
Kelsey Stephen Michael	See Remarks	Oct 13 '25	Option Exercise	4.73	25,000	118,250	309,047	Oct 15 05:09 PM
Kelsey Stephen Michael	See Remarks	Oct 13 '25	Sale	48.54	25,000	1,213,540	284,047	Oct 15 05:09 PM
Cislini Jeff	General Counsel	Sep 24 '25	Sale	44.26	1,799	79,624	50,425	Sep 26 04:13 PM
JEFFREY TODD CISLINI	Officer	Sep 24 '25	Proposed Sale	44.21	1,799	79,525		Sep 24 04:21 PM
Wei Lin	Chief Medical Officer	Sep 16 '25	Sale	45.82	2,160	98,982	88,339	Sep 18 04:39 PM
Kelsey Stephen Michael	See Remarks	Sep 16 '25	Sale	45.82	5,367	245,942	284,047	Sep 18 04:38 PM
GOLDSMITH MARK A	See Remarks	Sep 16 '25	Sale	45.82	13,411	614,558	452,309	Sep 18 04:37 PM
Horn Margaret A	Chief Operating Officer	Sep 16 '25	Sale	45.82	4,775	218,814	145,900	Sep 18 04:36 PM
Cislini Jeff	General Counsel	Sep 16 '25	Sale	45.82	1,869	85,647	52,224	Sep 18 04:35 PM
Anders Jack	Chief Financial Officer	Sep 16 '25	Sale	45.82	2,320	106,314	110,994	Sep 18 04:34 PM
Wei Lin	Officer	Sep 15 '25	Proposed Sale	46.55	2,131	99,198		Sep 15 09:32 PM
Kelsey Stephen Michael	Officer	Sep 15 '25	Proposed Sale	46.55	5,296	246,529		Sep 15 09:28 PM
Horn Margaret A	Officer	Sep 15 '25	Proposed Sale	46.55	4,712	219,344		Sep 15 09:24 PM
GOLDSMITH MARK A	Officer	Sep 15 '25	Proposed Sale	46.55	13,236	616,136		Sep 15 09:20 PM
Cislini Jeff	Officer	Sep 15 '25	Proposed Sale	46.55	1,842	85,745		Sep 15 09:18 PM
Anders Jack	Officer	Sep 15 '25	Proposed Sale	46.55	2,128	99,058		Sep 15 09:14 PM
Kelsey Stephen Michael	See Remarks	Sep 11 '25	Option Exercise	4.73	100,000	473,000	389,414	Sep 15 08:51 PM
Kelsey Stephen Michael	See Remarks	Sep 15 '25	Option Exercise	4.73	25,000	118,250	314,414	Sep 15 08:51 PM
Kelsey Stephen Michael	See Remarks	Sep 11 '25	Sale	44.08	100,000	4,408,482	289,414	Sep 15 08:51 PM
Kelsey Stephen Michael	See Remarks	Sep 15 '25	Sale	45.97	25,000	1,149,272	289,414	Sep 15 08:51 PM
STEPHEN M. KELSEY	Officer	Sep 11 '25	Proposed Sale	40.45	150,000	6,067,500		Sep 11 04:30 PM
Anders Jack	Chief Financial Officer	Sep 03 '25	Option Exercise	9.53	5,238	49,917	118,552	Sep 04 07:05 PM
Anders Jack	Chief Financial Officer	Sep 02 '25	Option Exercise	3.52	4,762	16,756	118,076	Sep 04 07:05 PM
Anders Jack	Chief Financial Officer	Sep 03 '25	Sale	40.17	5,238	210,432	113,314	Sep 04 07:05 PM
Anders Jack	Chief Financial Officer	Sep 02 '25	Sale	40.02	4,762	190,560	113,314	Sep 04 07:05 PM
JACK LEE ANDERS	Officer	Sep 02 '25	Proposed Sale	37.97	10,000	379,700		Sep 02 04:41 PM
GOLDSMITH MARK A	See Remarks	Jun 30 '25	Option Exercise	0.54	37,000	19,980	465,720	Jul 02 04:11 PM
Cislini Jeff	General Counsel	Jun 20 '25	Sale	39.61	1,912	75,736	54,093	Jun 23 04:07 PM
JEFFREY TODD CISLINI	Officer	Jun 20 '25	Proposed Sale	39.93	1,912	76,346		Jun 20 04:23 PM
Horn Margaret A	Chief Operating Officer	Jun 16 '25	Sale	39.83	3,510	139,803	150,675	Jun 18 04:06 PM
GOLDSMITH MARK A	See Remarks	Jun 16 '25	Sale	39.83	13,496	537,546	428,720	Jun 18 04:06 PM
Cislini Jeff	General Counsel	Jun 16 '25	Sale	39.83	1,878	74,801	56,005	Jun 18 04:06 PM
Anders Jack	Chief Financial Officer	Jun 16 '25	Sale	39.83	2,170	86,431	113,314	Jun 18 04:05 PM
Kelsey Stephen Michael	See Remarks	Jun 16 '25	Sale	39.83	4,289	170,831	289,414	Jun 18 04:05 PM
Wei Lin	Chief Medical Officer	Jun 16 '25	Sale	39.83	2,173	86,551	90,499	Jun 18 04:05 PM
Wei Lin	Officer	Jun 16 '25	Proposed Sale	40.79	2,131	86,923		Jun 13 05:25 PM
Kelsey Stephen Michael	Officer	Jun 16 '25	Proposed Sale	40.79	3,732	152,228		Jun 13 05:05 PM
Horn Margaret A	Officer	Jun 16 '25	Proposed Sale	40.79	3,320	135,423		Jun 13 05:03 PM
GOLDSMITH MARK A	Officer	Jun 16 '25	Proposed Sale	40.79	13,235	539,856		Jun 13 05:00 PM
Cislini Jeff	Officer	Jun 16 '25	Proposed Sale	40.79	1,842	75,135		Jun 13 04:58 PM
Anders Jack	Officer	Jun 16 '25	Proposed Sale	40.79	2,127	86,760		Jun 13 04:55 PM
Cislini Jeff	General Counsel	Mar 20 '25	Sale	38.71	2,041	79,008	57,723	Mar 24 04:55 PM
JEFFREY TODD CISLINI	Officer	Mar 20 '25	Proposed Sale	38.75	2,041	79,089		Mar 20 04:32 PM
Cislini Jeff	General Counsel	Mar 17 '25	Sale	39.04	1,458	56,921	59,764	Mar 19 05:43 PM
GOLDSMITH MARK A	See Remarks	Mar 17 '25	Sale	39.04	11,738	458,255	441,564	Mar 19 05:43 PM
Anders Jack	Chief Financial Officer	Mar 17 '25	Sale	39.04	1,864	72,771	115,006	Mar 19 05:42 PM
Horn Margaret A	Chief Operating Officer	Mar 17 '25	Sale	39.04	3,058	119,385	153,533	Mar 19 05:41 PM
Kelsey Stephen Michael	See Remarks	Mar 17 '25	Sale	39.04	3,294	128,599	293,051	Mar 19 05:40 PM
Anders Jack	Officer	Mar 17 '25	Proposed Sale	38.89	2,108	81,980		Mar 14 05:42 PM
Cislini Jeff	Officer	Mar 17 '25	Proposed Sale	38.89	1,650	64,168		Mar 14 05:14 PM
Kelsey Stephen Michael	Officer	Mar 17 '25	Proposed Sale	38.89	3,611	140,432		Mar 14 04:47 PM
Horn Margaret A	Officer	Mar 17 '25	Proposed Sale	38.89	3,406	132,459		Mar 14 04:18 PM
GOLDSMITH MARK A	Officer	Mar 17 '25	Proposed Sale	38.89	11,890	462,402		Mar 14 04:09 PM

Open in Screener

CRWV

CoreWeave Inc

Feb 13 • 04:00PM ET

96.04

+0.34 0.36 %

Technology • Software - Infrastructure • USA • NASD

Held by: VTI VO VUG VOT VXF ARKK SKYY ARTY FDN ARKW

Index	-	P/E	-	EPS (ttm)	-1.82	Insider Own	40.63%	Shs Outstand	384.86M	Perf Week	6.77%
Market Cap	50.06B	Forward P/E	-	EPS next Y	-0.28	Insider Trans	-17.37%	Shs Float	312.64M	Perf Month	6.95%
Enterprise Value	66.33B	PEG	-	EPS next Q	-0.50	Inst Own	47.96%	Short Float	14.93%	Perf Quarter	12.42%
Income	-824.73M	P/S	11.62	EPS this Y	-397.37%	Inst Trans	23.71%	Short Ratio	1.61	Perf Half Y	-3.48%
Sales	4.31B	P/B	12.32	EPS next Y	78.99%	ROA	-3.26%	Short Interest	46.67M	Perf YTD	34.12%
Book/sh	7.79	P/C	19.72	EPS next 5Y	-	ROE	-29.17%	52W High	187.00 -48.64%	Perf Year	-
Cash/sh	4.87	P/FCF	-	EPS past 3/5Y	-449.58% -	ROIC	-4.44%	52W Low	33.51 186.56%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	30.78	Sales past 3/5Y	1000.00% -	Gross Margin	49.23%	Volatility	8.63% 9.47%	Perf 5Y	-
Dividend TTM	-	EV/Sales	15.40	EPS Y/Y TTM	19.90%	Oper. Margin	3.63%	ATR (14)	8.68	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.49	Sales Y/Y TTM	235.40%	Profit Margin	-19.15%	RSI (14)	54.48	Recom	1.97
Dividend Gr. 3/5Y	- -	Current Ratio	0.49	EPS Q/Q	75.23%	SMA20	1.84%	Beta	-	Target Price	124.71
Payout	-	Debt/Eq	4.85	Sales Q/Q	133.70%	SMA50	11.70%	Rel Volume	0.80	Prev Close	95.70
Employees	-	LT Debt/Eq	3.79	Earnings	Feb 26 AMC	SMA200	-11.08%	Avg Volume	29.01M	Price	96.04
IPO	Mar 28, 2025	Option/Short	Yes / Yes	EPS/Sales Surpr.	79.47% 6.13%	Trades		Volume	23,076,686	Change	0.36%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-27-26	Upgrade	Deutsche Bank	Hold → Buy	$140
Jan-26-26	Upgrade	DA Davidson	Neutral → Buy	$110
Jan-12-26	Resumed	Goldman	Neutral	$86
Jan-06-26	Initiated	Truist	Hold	$84
Jan-05-26	Upgrade	DA Davidson	Underperform → Neutral	$68
Dec-19-25	Resumed	Citigroup	Buy	$135
Dec-05-25	Initiated	Roth Capital	Buy	$110
Nov-11-25	Downgrade	JP Morgan	Overweight → Neutral	$110
Sep-30-25	Initiated	Evercore ISI	Outperform	$175
Sep-23-25	Upgrade	Wells Fargo	Equal Weight → Overweight	$170
Sep-23-25	Upgrade	Melius	Hold → Buy	$165
Sep-19-25	Initiated	Loop Capital	Buy	$165
Sep-16-25	Upgrade	Citizens JMP	Mkt Perform → Mkt Outperform	$180
Sep-16-25	Initiated	Raymond James	Outperform	$130
Aug-27-25	Initiated	Cantor Fitzgerald	Overweight	$116
Aug-21-25	Upgrade	H.C. Wainwright	Neutral → Buy	$180
Aug-21-25	Upgrade	Arete	Neutral → Buy	$180
Jul-31-25	Upgrade	Citigroup	Neutral → Buy	$160
Jul-17-25	Initiated	HSBC Securities	Reduce	$32
Jul-11-25	Initiated	Argus	Buy	$200

Show Previous Ratings

Today 08:41AM	Analysts Reaffirm Buy on CoreWeave (CRWV) Following Expanded NVIDIA Partnership and Growth Plans (Insider Monkey)
Feb-14-26 09:23AM	CoreWeave's (CRWV) AI Boom Story Now Competes With Securities Lawsuit (Insider Monkey)
Feb-13-26 02:12PM	Blackstone Wealth Fund Posts 20% Gain, 30% Tied to AI Bets (GuruFocus.com)
Feb-12-26 09:39AM	Stocks in OpenAIs Orbit Get Second Look as Traders Eye Rebound (Bloomberg)
09:00AM	CRWV Shares Pop 138% in a Year: Should Investors Hold or Lock in Gains? (Zacks)
08:47AM	Loading…
08:47AM	AI cloud firm Nebius posts surge in capex on GPU, data center expenses (Reuters)
08:43AM	Nebius Targets Fast-Growing Agentic AI Market With Tavily Acquisition (Zacks)
07:05AM	Amsterdam-based AI firm Nebius to build 240MW data centre near Lille, France (Reuters)
Feb-11-26 11:20AM	Dear CoreWeave Stock Fans, Mark Your Calendars for February 26 (Barchart)
Feb-10-26 11:19AM	Ahead of Q4 Earnings, CoreWeave Is Up 142% Over the Past Year (MarketBeat)
10:06AM	APLD Trades Near 52-Week High: Should You Buy, Sell or Hold the Stock? (Zacks)
08:37AM	Does ARENA Roll Out Give CoreWeave a Competitive Revenue Edge? (Zacks)
Feb-07-26 10:30AM	Crypto Currents: Strategy, Galaxy Digital report Q4 earnings results (TipRanks)
Feb-06-26 01:07PM	Nvidia Shares Surge on Big Techs $650 Billion AI-Spending Plan (Bloomberg) +20.50%
08:39AM	The Great Pivot: Bitcoin Miners Are Becoming AI's Landlords (MarketBeat)
08:30AM	Loading…
08:30AM	CoreWeave Introduces a New Brand Vision As the Cloud Built for This Moment (Business Wire)
Feb-05-26 05:30PM	Great Elm Group Q2 Earnings Call Highlights (MarketBeat) -9.47%
04:52PM	Hagens Berman Investigating Claims Against CoreWeave, Inc. (CRWV) Over Alleged Data Center Delays and Concealed Infrastructure Risks (PR Newswire)
04:45PM	Cathie Woods ARK Funds Buy the AMD Stock Drop (Barrons.com)
04:05PM	CoreWeave Announces Date of Fourth Quarter and Fiscal Year 2025 Financial Results and Conference Call (Business Wire)
08:00AM	Introducing CoreWeave ARENA, New Lab for AI Production Readiness (Business Wire)
07:45AM	Cathie Woods ARK Funds Bought the AMD Stock Dip (Barrons.com)
05:18AM	AMD Stock Got Hammered. Cathie Woods ARK Funds Bought the Dip. (Barrons.com)
04:20AM	CoreWeave, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CRWV (PR Newswire)
Feb-04-26 09:17PM	Cathie Wood Doubles Down On Tesla With $14.5 Million Stock Purchase, Ark Invest Pounces On AMD Dip (Benzinga) -8.44%
08:54PM	Owning the Operating System (Motley Fool)
06:30PM	Nvidia Has More Than 85% of Its Portfolio Invested in 1 Artificial Intelligence (AI) Stock. Should You Follow Suit? (Motley Fool)
03:11PM	Software's Meltdown Is Classic Doublethink. Don't Fall for It. (Barrons.com)
02:00PM	The IPO Market Faces a Busy Week. These Stocks Are Making Their Debuts. (Barrons.com)
07:20AM	CoreWeave's 2025 -- The Year Its Growth Story Became Clear (Motley Fool)
05:05AM	Loading…
05:05AM	2 Things CoreWeave Must Prove in 2026 (Motley Fool)
03:48AM	CoreWeave, IREN, Equinix, Other 'Terrestrial' Data Center Plays In Focus As Jim Chanos Slams 'Space' Narrative (Benzinga)
03:05AM	Galaxy Digital Q4 Earnings Call Highlights (MarketBeat)
Feb-03-26 08:51PM	CoreWeave, Inc. (CRWV): A Bull Case Theory (Insider Monkey)
04:58PM	Chip stocks inch lower after AMD results (MarketWatch)
02:46PM	The IPO Market Faces a Busy Week. These Stocks Are Making Their Debuts. (Barrons.com)
12:30PM	Galaxy Digital Stock Is Tumbling on an Earnings Miss. It's a Tale of Two Businesses. (Barrons.com)
11:41AM	Cathie Wood Loads Up Millions in Alphabet and CoreWeave Stock (GuruFocus.com)
11:40AM	Better Artificial Intelligence Stock: Applied Digital vs. CoreWeave (Motley Fool)
10:39AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool)
08:47AM	Hagens Berman Investigating Claims Against CoreWeave, Inc. (CRWV) Over Alleged Data Center Delays and Concealed Infrastructure Risks (PR Newswire)
07:02AM	NVIDIA Webinar Teases Co-Packaged Optics to Cut Power and Scale Gigawatt AI Factories (MarketBeat)
02:18AM	Cathie Wood's ARK buys over $70 million of crypto stocks as bitcoin slides (CoinDesk)
Feb-02-26 02:29PM	CoreWeaves CEO Explains Why This Is Not Your Fathers Tech Company (Barrons.com)
01:00PM	Insiders Rang in the New Year Selling These Stocks, Buyers Beware (MarketBeat)
11:33AM	Analysts revisit Nvidia-backed AI stock ahead of earnings (TheStreet)
08:27AM	CoreWeave Partner Core Scientific Momentum Surges As Keefe, Bruyette & Woods Cheer AI Infrastructure Transition (Benzinga)
08:07AM	NVIDIA Just Made Another Smart Bet on AI (24/7 Wall St.)
08:03AM	AI Stocks Checkup: Weekly Moves And Who's Leading Or Lagging In 2026 (Investor's Business Daily)
07:45AM	Nvidia Stock Drops. Why Its $100 Billion OpenAI Investment Is in Question. (Barrons.com)
Feb-01-26 05:43PM	Nvidia Just Piled $2 Billion Into This Key AI Partner. Should Investors Follow Suit? (Motley Fool)
05:20PM	CoreWeave's CEO Explains Why This Is Not Your Father's Tech Company (Barrons.com)
01:30PM	Is CoreWeave a Buy After This Big News From Nvidia? (Motley Fool)
09:50AM	1 Brilliant Stock That Nvidia Owns That You Should Buy Hand Over Fist in 2026 (Motley Fool)
05:06AM	OpenAI Investment Was Never a Commitment, Nvidias Huang Says (Bloomberg)
Jan-31-26 01:00AM	CoreWeave's CEO Explains Why This Is Not Your Father's Tech Company (Barrons.com)
Jan-30-26 03:07PM	Microsoft Staged AI's Greatest Test Case. It May Not Be Working. (Barrons.com) -6.37%
02:58PM	Deutsche Bank Upgrades CoreWeave (CRWV) to Buy Ahead of Q4 2025 Report (Insider Monkey)
02:08PM	This Analyst Just Raised Their CoreWeave Price Target by 40%. Should You Buy CRWV Stock Now? (Barchart)
09:53AM	OpenAI Is Planning a Huge IPO. Why Amazon Could Become a Major Investor. (Barrons.com)
07:28AM	HSBC Cuts CoreWeave (CRWV) Price Target, Flags High Funding Needs and Rising Debt Costs (Insider Monkey)
03:47AM	Amazon Mulls $50 Billion Investment in OpenAI, Report Says. What's in it for Both. (Barrons.com)
Jan-29-26 11:35PM	What Anthropic and OpenAI's Recent News Mean for AI Stock Investors (Motley Fool) -6.12%
10:50PM	Meta Platforms Just Said It Will Spend $135 Billion on AI This Year. This Hypergrowth Stock Could Be the Biggest Winner (Motley Fool)
06:20PM	The Artificial Intelligence (AI) Stock That Refuses to Stay Down (Motley Fool)
02:49PM	Is Oracle Still Worth Chasing, or Is the Stock Set to Plunge More? (24/7 Wall St.)
12:39PM	5 Stocks to Buy in February: Last Year's Winners Aren't Done Yet (MarketBeat)
10:25AM	CRVW vs. GOOGL: Which Stock Wins the AI Infrastructure Race? (Zacks)
08:17AM	Mizuho Sees Long-Term Upside in CoreWeave (CRWV) Despite Near-Term Risks (Insider Monkey)
04:30AM	CoreWeave, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CRWV (PR Newswire)
02:13AM	The Artificial Intelligence (AI) Stock That's Quietly Building the Future of Cloud Computing (Motley Fool)
Jan-28-26 06:05PM	These AI Cloud Stocks Are Starting to Soar Again Thanks to Nvidia: ANET, CRWV (Zacks)
04:18PM	CoreWeave's NVIDIA Boost Fueled a Rally-Now Comes the Hard Part (MarketBeat)
04:11PM	OKLO: Deja vu? (An 11x Return Last Time this Occured) (Zacks)
04:05PM	Meta expects annual capital expenditures to rise on superintelligence push (Reuters)
02:05PM	CoreWeave (CRWV) Jumps 10.7% on Billion-Dollar Backing (Insider Monkey)
01:28PM	CoreWeave Stock Earns RS Rating Upgrade (Investor's Business Daily)
12:52PM	Jim Cramer Calls the NVIDIA Deal a "Fantastic Verification for CoreWeave" (Insider Monkey)
11:01AM	Nvidia's AI Boom Is Being Financed By Wall Street's Newest Asset Class: GPU Debt (Benzinga)
10:22AM	Why Applied Digital Surged After Nvidia Bet $2 Billion on CoreWeave (24/7 Wall St.)
08:15AM	Nvidia (NASDAQ: NVDA) Stock Price Prediction for 2026: Where Will It Be in 1 Year (Jan 28) (24/7 Wall St.)
04:49AM	Zacks Investment Ideas feature highlights Iren, CoreWeave and CoreWeave (Zacks)
Jan-27-26 10:05PM	Prediction: This AI Infrastructure Stock Will Be the Biggest Beneficiary of OpenAI's Growth by End of 2026 (Motley Fool) +10.73%
09:35PM	Forget Applied Digital: This AI-Ready Data Center Powerhouse Already Boasts the Scale It Dreams Of (Motley Fool)
06:24PM	Nvidia Just Gave You a $2 Billion Reason to Buy CoreWeave Stock (Barchart)
04:38PM	These Stocks Are Todays Movers: UnitedHealth, Humana, Micron, Corning, CoreWeave, UPS, GM, and More (Barrons.com)
04:34PM	S&P 500 Posts a Record High on Tech Strength and Solid Corporate Earnings (Barchart)
03:26PM	Iren Limited vs. CoreWeave: Accelerating AI Momentum (Zacks)
02:04PM	Is AI In A Bubble? What Wall Street Thinks Now (Investor's Business Daily)
01:25PM	CoreWeave Stock Soars Following Expanded Nvidia Collaboration (Benzinga)
01:12PM	Market Movers: Affirm Upgraded to a Buy Rating (24/7 Wall St.)
12:15PM	Why CoreWeave Stock is Soaring (Again) Today (Motley Fool)
12:03PM	Is Nvidia Investing In CoreWeave, Or Its Own Next Quarter? (Benzinga)
11:20AM	This AI Stock Just Landed $2 Billion From Nvidia -- Is It the Next Big Infrastructure Play? (Motley Fool)
11:19AM	Nvidia Just Doubled Down on Its Largest AI Holding. Should Investors Follow Suit? (Motley Fool)
11:15AM	Broader Market Rallies on Tech Strength and Solid Earnings (Barchart)
11:15AM	Why Nvidia stock is on sale (Yahoo Finance)
11:07AM	CoreWeave Stock Pops After Deutsche Bank Hikes Price Target to $140 (GuruFocus.com)
10:45AM	Pfizer, Merck, CoreWeave, Zoom: Top Analyst Calls (Yahoo Finance Video)
10:09AM	CoreWeave Stock Rises Again. Wall Street Loves Nvidias Investment. (Barrons.com)

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Intrator Michael N	CEO and President	Feb 11 '26	Sale	93.63	50,000	4,681,611	0	Feb 13 07:56 PM
Intrator Michael N	CEO and President	Feb 11 '26	Sale	93.63	32,455	3,038,833	5,763,868	Feb 13 07:56 PM
McBee Brannin	Chief Development Officer	Feb 09 '26	Sale	95.95	33,335	3,198,377	0	Feb 11 08:56 PM
McBee Brannin	Chief Development Officer	Feb 09 '26	Sale	95.81	5,000	479,069	0	Feb 11 08:55 PM
McBee Brannin	Chief Development Officer	Feb 09 '26	Sale	95.95	102,830	9,866,210	248,664	Feb 11 08:54 PM
McBee Brannin	Chief Development Officer	Feb 09 '26	Sale	95.94	25,500	2,446,574	0	Feb 11 08:54 PM
OMNADORA CAPITAL LLC	Director	Feb 11 '26	Proposed Sale	95.11	50,000	4,755,500		Feb 11 04:30 PM
MICHAEL INTRATOR	Director	Feb 11 '26	Proposed Sale	95.11	32,455	3,086,795		Feb 11 04:30 PM
CANIS MAJOR SM TRUST	Officer	Feb 09 '26	Proposed Sale	89.95	500	44,975		Feb 09 04:33 PM
BRANNIN MCBEE	Officer	Feb 09 '26	Proposed Sale	89.95	102,830	9,249,558		Feb 09 04:33 PM
Canis Major 2024 Irrevocable T	Officer	Feb 09 '26	Proposed Sale	89.95	3,000	269,850		Feb 09 04:32 PM
CANIS MAJOR 2025 FAMILY TRUST	Officer	Feb 09 '26	Proposed Sale	89.95	1,000	89,950		Feb 09 04:32 PM
CANIS MINOR 2025 FAMILY TRUST	Officer	Feb 09 '26	Proposed Sale	89.95	1,000	89,950		Feb 09 04:32 PM
CANIS MAJOR 2025 GRAT	Officer	Feb 09 '26	Proposed Sale	89.95	25,000	2,248,750		Feb 09 04:32 PM
CANIS MINOR 2025 GRAT	Officer	Feb 09 '26	Proposed Sale	89.95	8,335	749,733		Feb 09 04:32 PM
Venturo Brian M	Chief Strategy Officer	Feb 04 '26	Sale	85.00	281,250	23,905,394	0	Feb 06 09:07 PM
Goldberg Chen	SVP of Engineering	Feb 05 '26	Sale	79.69	17,985	1,433,291	42,859	Feb 06 09:06 PM
Chen Goldberg	Officer	Feb 05 '26	Proposed Sale	79.69	17,985	1,433,291		Feb 05 07:13 PM
McBee Brannin	Chief Development Officer	Feb 02 '26	Sale	90.43	35,335	3,195,445	0	Feb 04 09:25 PM
McBee Brannin	Chief Development Officer	Feb 02 '26	Sale	90.43	102,830	9,298,596	248,664	Feb 04 09:23 PM
McBee Brannin	Chief Development Officer	Feb 02 '26	Sale	90.44	28,500	2,577,539	0	Feb 04 09:23 PM
WEST CLAY CAPITAL LLC	Director	Feb 04 '26	Proposed Sale	90.06	281,250	25,329,375		Feb 04 04:48 PM
CANIS MINOR 2025 GRAT	Officer	Feb 02 '26	Proposed Sale	93.19	8,335	776,739		Feb 02 04:30 PM
CANIS MAJOR 2025 GRAT	Officer	Feb 02 '26	Proposed Sale	93.19	25,000	2,329,750		Feb 02 04:30 PM
CANIS MINOR 2025 FAMILY TRUST	Officer	Feb 02 '26	Proposed Sale	93.19	1,000	93,190		Feb 02 04:30 PM
CANIS MAJOR 2025 FAMILY TRUST	Officer	Feb 02 '26	Proposed Sale	93.19	1,000	93,190		Feb 02 04:30 PM
Canis Major 2024 Irrevocable T	Officer	Feb 02 '26	Proposed Sale	93.19	3,000	279,570		Feb 02 04:30 PM
BRANNIN MCBEE	Officer	Feb 02 '26	Proposed Sale	93.19	102,830	9,582,728		Feb 02 04:29 PM
CANIS MAJOR SM TRUST	Officer	Feb 02 '26	Proposed Sale	93.19	500	46,595		Feb 02 04:28 PM
Intrator Michael N	CEO and President	Jan 28 '26	Sale	106.08	50,000	5,304,191	0	Jan 30 08:12 PM
Intrator Michael N	CEO and President	Jan 28 '26	Sale	106.08	32,456	3,443,055	5,796,323	Jan 30 08:12 PM
Baker Jeff	Principal Accounting Officer	Jan 29 '26	Sale	103.78	5,143	533,760	39,304	Jan 30 08:11 PM
Jeff Baker	Officer	Jan 29 '26	Proposed Sale	103.78	5,143	533,760		Jan 29 09:53 PM
McBee Brannin	Chief Development Officer	Jan 26 '26	Sale	101.45	33,335	3,381,893	0	Jan 28 05:44 PM
McBee Brannin	Chief Development Officer	Jan 26 '26	Sale	101.49	2,000	202,983	0	Jan 28 05:43 PM
McBee Brannin	Chief Development Officer	Jan 26 '26	Sale	101.45	25,500	2,587,043	0	Jan 28 05:42 PM
McBee Brannin	Chief Development Officer	Jan 26 '26	Sale	101.45	102,830	10,432,315	248,664	Jan 28 05:41 PM
McBee Brannin	Chief Development Officer	Jan 26 '26	Sale	101.49	3,000	304,478	0	Jan 28 05:41 PM
OMNADORA CAPITAL LLC	Director	Jan 28 '26	Proposed Sale	108.86	50,000	5,443,000		Jan 28 04:21 PM
MICHAEL INTRATOR	Director	Jan 28 '26	Proposed Sale	108.86	32,456	3,533,160		Jan 28 04:21 PM
CANIS MINOR 2025 GRAT	Officer	Jan 26 '26	Proposed Sale	92.98	8,335	774,988		Jan 26 04:28 PM
CANIS MAJOR 2025 GRAT	Officer	Jan 26 '26	Proposed Sale	92.98	25,000	2,324,500		Jan 26 04:28 PM
CANIS MINOR 2025 FAMILY TRUST	Officer	Jan 26 '26	Proposed Sale	92.98	1,000	92,980		Jan 26 04:28 PM
CANIS MAJOR 2025 FAMILY TRUST	Officer	Jan 26 '26	Proposed Sale	92.98	1,000	92,980		Jan 26 04:28 PM
Canis Major 2024 Irrevocable T	Officer	Jan 26 '26	Proposed Sale	92.98	3,000	278,940		Jan 26 04:27 PM
BRANNIN MCBEE	Officer	Jan 26 '26	Proposed Sale	92.98	102,830	9,561,133		Jan 26 04:27 PM
CANIS MAJOR SM TRUST	Officer	Jan 26 '26	Proposed Sale	92.98	500	46,490		Jan 26 04:27 PM
Venturo Brian M	Chief Strategy Officer	Jan 21 '26	Sale	91.77	281,250	25,810,087	0	Jan 23 04:37 PM
McBee Brannin	Chief Development Officer	Jan 20 '26	Sale	95.29	35,335	3,367,224	0	Jan 22 08:41 PM
McBee Brannin	Chief Development Officer	Jan 20 '26	Sale	95.29	102,835	9,799,593	248,664	Jan 22 08:40 PM
McBee Brannin	Chief Development Officer	Jan 20 '26	Sale	95.29	28,500	2,715,885	0	Jan 22 08:40 PM
WEST CLAY CAPITAL LLC	Director	Jan 21 '26	Proposed Sale	95.22	281,250	26,780,625		Jan 21 04:23 PM
CANIS MINOR 2025 GRAT	Officer	Jan 20 '26	Proposed Sale	101.23	8,335	843,752		Jan 20 04:37 PM
CANIS MAJOR 2025 GRAT	Officer	Jan 20 '26	Proposed Sale	101.23	25,000	2,530,750		Jan 20 04:37 PM
CANIS MINOR 2025 FAMILY TRUST	Officer	Jan 20 '26	Proposed Sale	101.23	1,000	101,230		Jan 20 04:37 PM
CANIS MAJOR 2025 FAMILY TRUST	Officer	Jan 20 '26	Proposed Sale	101.23	1,000	101,230		Jan 20 04:37 PM
Canis Major 2024 Irrevocable T	Officer	Jan 20 '26	Proposed Sale	101.23	3,000	303,690		Jan 20 04:37 PM
BRANNIN MCBEE	Officer	Jan 20 '26	Proposed Sale	101.23	102,835	10,409,987		Jan 20 04:36 PM
CANIS MAJOR SM TRUST	Officer	Jan 20 '26	Proposed Sale	101.23	500	50,615		Jan 20 04:36 PM
Intrator Michael N	CEO and President	Jan 14 '26	Sale	89.39	50,000	4,469,641	0	Jan 16 06:19 PM
Intrator Michael N	CEO and President	Jan 14 '26	Sale	89.39	32,455	2,901,244	5,828,779	Jan 16 06:19 PM
McBee Brannin	Chief Development Officer	Jan 12 '26	Sale	88.77	8,835	784,274	0	Jan 14 09:04 PM
McBee Brannin	Chief Development Officer	Jan 12 '26	Sale	88.77	26,000	2,308,081	0	Jan 14 09:03 PM
McBee Brannin	Chief Development Officer	Jan 12 '26	Sale	88.77	26,000	2,308,082	0	Jan 14 09:02 PM
McBee Brannin	Chief Development Officer	Jan 12 '26	Sale	88.78	102,835	9,129,573	248,664	Jan 14 09:01 PM
McBee Brannin	Chief Development Officer	Jan 12 '26	Sale	88.62	3,000	265,864	0	Jan 14 09:01 PM
OMNADORA CAPITAL LLC	Director	Jan 14 '26	Proposed Sale	87.48	50,000	4,374,000		Jan 14 04:27 PM
MICHAEL INTRATOR	Director	Jan 14 '26	Proposed Sale	87.48	32,455	2,839,163		Jan 14 04:27 PM
CANIS MINOR 2025 GRAT	Officer	Jan 12 '26	Proposed Sale	80.14	8,335	667,967		Jan 12 04:25 PM
CANIS MAJOR 2025 GRAT	Officer	Jan 12 '26	Proposed Sale	80.14	25,000	2,003,500		Jan 12 04:25 PM
CANIS MINOR 2025 FAMILY TRUST	Officer	Jan 12 '26	Proposed Sale	80.14	1,000	80,140		Jan 12 04:24 PM
CANIS MAJOR 2025 FAMILY TRUST	Officer	Jan 12 '26	Proposed Sale	80.14	1,000	80,140		Jan 12 04:24 PM
Canis Major 2024 Irrevocable T	Officer	Jan 12 '26	Proposed Sale	80.14	3,000	240,420		Jan 12 04:24 PM
BRANNIN MCBEE	Officer	Jan 12 '26	Proposed Sale	80.14	102,835	8,241,197		Jan 12 04:24 PM
CANIS MAJOR SM TRUST	Officer	Jan 12 '26	Proposed Sale	80.14	500	40,070		Jan 12 04:23 PM
Venturo Brian M	Chief Strategy Officer	Jan 07 '26	Sale	78.11	154,479	12,065,655	0	Jan 08 07:42 PM
Venturo Brian M	Chief Strategy Officer	Jan 06 '26	Sale	76.15	52,473	3,996,070	223,580	Jan 08 07:42 PM
Intrator Michael N	CEO and President	Jan 06 '26	Sale	76.15	61,386	4,674,750	5,861,234	Jan 08 07:40 PM
McBee Brannin	Chief Development Officer	Jan 05 '26	Sale	79.28	8,835	700,454	0	Jan 07 08:03 PM
McBee Brannin	Chief Development Officer	Jan 05 '26	Sale	79.28	27,000	2,140,616	0	Jan 07 08:01 PM
McBee Brannin	Chief Development Officer	Jan 05 '26	Sale	79.28	102,835	8,153,026	248,664	Jan 07 07:59 PM
McBee Brannin	Chief Development Officer	Jan 05 '26	Sale	79.28	28,000	2,219,899	0	Jan 07 07:59 PM
WEST CLAY CAPITAL LLC	Director	Jan 07 '26	Proposed Sale	77.94	154,479	12,040,093		Jan 07 04:25 PM
MICHAEL INTRATOR	Director	Jan 06 '26	Proposed Sale	76.86	61,386	4,718,128		Jan 06 04:32 PM
BRIAN VENTURO	Director	Jan 06 '26	Proposed Sale	76.86	52,473	4,033,075		Jan 06 04:32 PM
CANIS MINOR 2025 GRAT	Officer	Jan 05 '26	Proposed Sale	79.32	8,335	661,132		Jan 05 04:36 PM
CANIS MAJOR 2025 GRAT	Officer	Jan 05 '26	Proposed Sale	79.32	25,000	1,983,000		Jan 05 04:35 PM
CANIS MINOR 2025 FAMILY TRUST	Officer	Jan 05 '26	Proposed Sale	79.32	1,000	79,320		Jan 05 04:35 PM
CANIS MAJOR 2025 FAMILY TRUST	Officer	Jan 05 '26	Proposed Sale	79.32	1,000	79,320		Jan 05 04:35 PM
Canis Major 2024 Irrevocable T	Officer	Jan 05 '26	Proposed Sale	79.32	3,000	237,960		Jan 05 04:35 PM
BRANNIN MCBEE	Officer	Jan 05 '26	Proposed Sale	79.32	102,835	8,156,872		Jan 05 04:34 PM
CANIS MAJOR SM TRUST	Officer	Jan 05 '26	Proposed Sale	79.32	500	39,660		Jan 05 04:34 PM
Venturo Brian M	Chief Strategy Officer	Dec 31 '25	Sale	72.57	65,940	4,785,363	276,053	Jan 02 09:13 PM
McBee Brannin	Chief Development Officer	Dec 31 '25	Sale	72.57	57,636	4,182,723	248,664	Jan 02 09:12 PM
Intrator Michael N	CEO and President	Dec 31 '25	Sale	72.39	111,427	8,065,759	5,922,620	Jan 02 09:11 PM
Intrator Michael N	CEO and President	Dec 31 '25	Sale	71.94	50,000	3,596,755	0	Jan 02 09:11 PM
Michael Intrator	Officer	Dec 31 '25	Proposed Sale	72.57	78,971	5,731,034		Dec 31 09:20 PM
Brian Venturo	Officer	Dec 31 '25	Proposed Sale	72.57	65,940	4,785,363		Dec 31 08:19 PM
Brannin McBee	Officer	Dec 31 '25	Proposed Sale	72.57	57,636	4,182,723		Dec 31 08:07 PM
McBee Brannin	Chief Development Officer	Dec 29 '25	Sale	75.63	33,835	2,558,796	0	Dec 31 05:56 PM

Open in Screener

APGE

Apogee Therapeutics Inc

Feb 13 • 04:00PM ET

67.78

-1.53 -2.21 %

Healthcare • Biotechnology • USA • NASD

APGE Apogee Therapeutics Inc daily Stock Chart

Peers: VRTX REGN BMRN SRPT IONS ALNY QURE CRSP NTLA SGMO

| Held by: VTI IWM XBI VXF TCAF IBB IWO SCHA VTWO VHT

Index	RUT	P/E	-	EPS (ttm)	-4.32	Insider Own	29.67%	Shs Outstand	59.32M	Perf Week	8.90%
Market Cap	4.63B	Forward P/E	-	EPS next Y	-4.90	Insider Trans	-8.74%	Shs Float	48.05M	Perf Month	-17.77%
Enterprise Value	4.11B	PEG	-	EPS next Q	-1.05	Inst Own	75.58%	Short Float	18.55%	Perf Quarter	7.42%
Income	-253.67M	P/S	-	EPS this Y	-27.53%	Inst Trans	3.65%	Short Ratio	9.18	Perf Half Y	77.81%
Sales	0.00M	P/B	8.42	EPS next Y	-16.45%	ROA	-36.18%	Short Interest	8.91M	Perf YTD	-10.20%
Book/sh	8.05	P/C	8.78	EPS next 5Y	-21.06%	ROE	-38.41%	52W High	84.56 -19.84%	Perf Year	86.93%
Cash/sh	7.72	P/FCF	-	EPS past 3/5Y	-105.02% -	ROIC	-42.84%	52W Low	26.20 158.70%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.22% 6.33%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-58.35%	Oper. Margin	-	ATR (14)	4.18	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	15.86	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	45.58	Recom	1.25
Dividend Gr. 3/5Y	- -	Current Ratio	15.86	EPS Q/Q	-28.18%	SMA20	-3.00%	Beta	1.39	Target Price	104.29
Payout	-	Debt/Eq	0.02	Sales Q/Q	-	SMA50	-8.70%	Rel Volume	1.20	Prev Close	69.31
Employees	196	LT Debt/Eq	0.01	Earnings	Nov 10 BMO	SMA200	31.16%	Avg Volume	970.74K	Price	67.78
IPO	Jul 14, 2023	Option/Short	Yes / Yes	EPS/Sales Surpr.	5.69% -	Trades		Volume	1,166,992	Change	-2.21%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-22-26	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$83
Jan-07-26	Initiated	Wolfe Research	Peer Perform
Dec-17-25	Initiated	Stephens	Overweight	$95
Dec-10-25	Initiated	Deutsche Bank	Buy	$103
Nov-03-25	Initiated	Craig Hallum	Buy	$109
Oct-21-25	Initiated	Mizuho	Outperform	$105
Sep-25-25	Initiated	RBC Capital Mkts	Outperform	$60
Jul-07-25	Reiterated	BTIG Research	Buy	$100 → $115
Mar-13-25	Initiated	Citigroup	Buy	$95
Nov-25-24	Initiated	Canaccord Genuity	Buy	$89
May-10-24	Initiated	BofA Securities	Buy	$80
Dec-20-23	Initiated	BTIG Research	Buy	$43
Aug-08-23	Initiated	Wedbush	Outperform	$40
Aug-08-23	Initiated	TD Cowen	Outperform
Aug-08-23	Initiated	Stifel	Buy	$34
Aug-08-23	Initiated	Jefferies	Buy	$29
Aug-08-23	Initiated	Guggenheim	Buy	$29

Show Previous Ratings

Feb-12-26 09:07PM	Apogee Therapeutics touts quarterly-to-biannual AD dosing shift, expands asthma ambitions at conference (MarketBeat) +5.32%
Feb-05-26 08:00AM	Apogee Therapeutics to Participate at the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire)
Jan-30-26 07:39PM	Elastic NV, Acadia Healthcare, and More Stocks See Action From Activist Investors (Barrons.com) -6.39%
Jan-12-26 12:00PM	Funding for Risky Biotechs Is Returning (The Wall Street Journal)
Jan-07-26 09:41AM	Wayfair upgraded, Instacart initiated: Wall Street's top analyst calls (The Fly)
06:00AM	Loading…
Jan-06-26 06:00AM	Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook (GlobeNewswire)
Jan-05-26 04:01PM	Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1b Trial of APG777 in Patients with Mild-to-Moderate Asthma and 2026 Anticipated Milestones on January 6, 2026 (GlobeNewswire)
Dec-09-25 12:19AM	Strong Pipeline and Analyst Confidence Push Apogee Therapeutics Inc. (APGE) Toward Growth (Insider Monkey)
Nov-11-25 09:40AM	Is Apogee Therapeutics Inc. (APGE) Outperforming Other Medical Stocks This Year? (Zacks) +10.89%
Nov-10-25 07:10AM	Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results (GlobeNewswire)
07:00AM	Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody (GlobeNewswire)
Nov-03-25 07:30AM	Apogee Therapeutics to Participate in Upcoming Conferences (GlobeNewswire)
Oct-30-25 09:55AM	Wall Street Analysts Believe Apogee Therapeutics Inc. (APGE) Could Rally 69.3%: Here's is How to Trade (Zacks)
Oct-17-25 09:55PM	BTIG Maintains a Buy on Apogee Therapeutics (APGE) (Insider Monkey)
Oct-14-25 09:55AM	Does Apogee Therapeutics Inc. (APGE) Have the Potential to Rally 72.52% as Wall Street Analysts Expect? (Zacks)
04:01PM	Loading…
Oct-10-25 04:01PM	Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $345 Million (GlobeNewswire)
Oct-09-25 05:26PM	Why Apogee Therapeutics Stock Triumphed on Thursday (Motley Fool) +12.64%
01:08PM	Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out (Investor's Business Daily)
Oct-08-25 09:52PM	Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering (GlobeNewswire) +18.90%
04:01PM	Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering (GlobeNewswire)
Sep-30-25 04:00AM	RBC Capital Initiates Coverage of Apogee Therapeutics (APGE) With an Outperform Rating (Insider Monkey)
Sep-15-25 09:09AM	BofA Raises Apogee Therapeutics (APGE) PT to $87 Following Positive Phase 2 APEX Trial Results for Atopic Dermatitis (Insider Monkey)
Sep-11-25 07:30AM	Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress (GlobeNewswire)
Sep-03-25 07:30AM	Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum (GlobeNewswire)
Aug-11-25 07:00AM	Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-06-25 09:55AM	Wall Street Analysts See a 152.41% Upside in Apogee Therapeutics Inc. (APGE): Can the Stock Really Move This High? (Zacks) -5.24%
Jul-31-25 11:38AM	Apogee Therapeutics, Inc. (APGE) Soars on Promising Phase 2 Results for Atopic Dermatitis Drug (Insider Monkey)
Jul-16-25 09:38AM	BTIG Raises PT on Apogee Therapeutics (APGE) to $115 From $100, Keeps a Buy Rating (Insider Monkey)
Jul-14-25 07:52AM	Canaccord Genuity Reiterated a Buy Rating on Apogee Therapeutics (APGE) (Insider Monkey)
Jul-08-25 03:31PM	Regeneron's Blockbuster Dupixent Faces a New Rival (Barrons.com) -7.21%
02:26PM	Loading…
02:26PM	Apogee Therapeutics (APGE) Falls 17%, Positive Trial Results Fail to Impress Investors (Insider Monkey)
Jul-07-25 04:27PM	Apogee Dives. But It Could Eventually Rival Sanofi's Biggest Moneymaker. (Investor's Business Daily) -17.32%
10:09AM	Apogee Reverses Lower Despite Promise For Twice-Yearly Eczema Shot (Investor's Business Daily)
06:00AM	Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis (GlobeNewswire)
Jul-06-25 06:00PM	Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025 (GlobeNewswire)
04:01AM	Apogee Therapeutics Shares Positive Interim Phase 1b Results for APG808 in Asthma (Insider Monkey)
Jun-09-25 09:55AM	Wall Street Analysts See a 129.09% Upside in Apogee Therapeutics Inc. (APGE): Can the Stock Really Move This High? (Zacks)
May-29-25 07:30AM	Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-21-25 09:55AM	Wall Street Analysts Think Apogee Therapeutics Inc. (APGE) Could Surge 132.72%: Read This Before Placing a Bet (Zacks)
May-12-25 02:21PM	Why Is Apogee Therapeutics Stock Trading Higher On Monday? (Benzinga) +6.14%
06:05AM	Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results (GlobeNewswire)
06:00AM	Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Ra Antibody, in Patients with Mild-to-Moderate Asthma (GlobeNewswire)
06:00AM	Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4R Antibody, in Patients with Mild-to-Moderate Asthma (GlobeNewswire)
May-05-25 09:55AM	Wall Street Analysts Believe Apogee Therapeutics Inc. (APGE) Could Rally 134%: Here's is How to Trade (Zacks)
May-01-25 08:00AM	Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference (GlobeNewswire)
Apr-14-25 08:04AM	Apogee Therapeutics: Engineering Biologic Dominance (Seeking Alpha)
Mar-26-25 05:50PM	Is Apogee Therapeutics (APGE) Among the Best IPO Stocks to Buy in 2025? (InsiderMonkey)
Mar-03-25 12:16PM	Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial (Benzinga)
06:05AM	Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results (GlobeNewswire)
06:00AM	Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990) (GlobeNewswire)
Mar-01-25 09:22AM	Is Apogee Therapeutics, Inc. (APGE) the Best Small-Cap Stock to Buy Now? (Insider Monkey)
Feb-28-25 04:00PM	Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025 (GlobeNewswire)
Feb-25-25 07:30AM	Apogee Therapeutics to Participate in Upcoming March Investor Conferences (GlobeNewswire)
Feb-03-25 07:00AM	Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis (GlobeNewswire)
Jan-30-25 03:44PM	Heres Why Apogee Therapeutics, Inc. (APGE) Will Double in 2025 (Insider Monkey) +5.41%
Jan-29-25 07:30AM	Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Dec-10-24 07:00AM	Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions (GlobeNewswire)
Dec-03-24 06:52AM	Apogee Therapeutics Advances in I&I Disease Treatments (TipRanks)
Dec-02-24 06:00AM	Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day (GlobeNewswire)
Nov-29-24 01:00PM	Apogee Therapeutics Announces Agenda for Virtual R&D Day (GlobeNewswire)
Nov-18-24 07:30AM	Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024 (GlobeNewswire)
Nov-13-24 07:21AM	Apogee reports Q3 EPS, expects cash to fund operations into Q1 of 2028 (TipRanks) -7.95%
Nov-12-24 07:00AM	Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results (GlobeNewswire) -5.14%
Nov-04-24 07:30AM	Apogee Therapeutics to Participate in Upcoming November Investor Conferences (GlobeNewswire)
Oct-24-24 08:00AM	Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases (GlobeNewswire)
Oct-16-24 07:00AM	Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting (GlobeNewswire)
Oct-07-24 04:50PM	Apogee Therapeutics, Inc. (APGE): A Hot Stock to Buy Now (Insider Monkey)
Oct-04-24 01:03PM	Wellington Management Group LLP Increases Stake in Apogee Therapeutics Inc (GuruFocus.com)
Sep-12-24 07:00AM	Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit (GlobeNewswire)
Sep-09-24 07:00AM	Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer (GlobeNewswire)
Sep-07-24 01:45AM	Insider Sale: Carl Dambkowski Sells Shares of Apogee Therapeutics Inc (APGE) (GuruFocus.com)
Aug-24-24 01:30AM	Insider Sale: CFO Jane Henderson Sells 6,000 Shares of Apogee Therapeutics Inc (APGE) (GuruFocus.com)
Aug-19-24 07:00AM	Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases (GlobeNewswire) +10.59%
Aug-12-24 06:30AM	Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results (GlobeNewswire) +9.78%
Aug-10-24 01:00AM	Apogee Therapeutics Inc (APGE) CEO Michael Henderson Sells 40,000 Shares (GuruFocus.com)
01:00AM	Insider Sale: Carl Dambkowski Sells 7,335 Shares of Apogee Therapeutics Inc (APGE) (GuruFocus.com)
Jul-18-24 08:00AM	NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors (GlobeNewswire)
Jul-06-24 01:00AM	Insider Sale: CEO Michael Henderson Sells 15,000 Shares of Apogee Therapeutics Inc (APGE) (GuruFocus.com)
01:00AM	Insider Sale: Carl Dambkowski Sells Shares of Apogee Therapeutics Inc (APGE) (GuruFocus.com)
May-28-24 07:30AM	Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD (GlobeNewswire)
May-23-24 07:30AM	Apogee Therapeutics to Participate in Upcoming June Investor Conferences (GlobeNewswire)
May-15-24 04:01PM	Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases (GlobeNewswire)
May-13-24 01:53PM	APGE Stock Earnings: Apogee Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
07:42AM	Apogee Therapeutics' Q1 Net Loss Widens (MT Newswires)
07:00AM	Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-10-24 10:13AM	BofA Securities Starts Coverage on Apogee Therapeutics With Buy Rating, $80 Price Target (MT Newswires)
May-08-24 01:28PM	Earnings Superstars: 3 Stocks Primed to Outperform This Quarter (InvestorPlace)
May-06-24 08:00AM	Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference (GlobeNewswire)
Apr-03-24 07:49AM	Paragons hub-and-spoke biotech model yields another reverse merger (BioPharma Dive)
Mar-28-24 11:01AM	Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why (Zacks)
Mar-25-24 07:00AM	Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Ra Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases (GlobeNewswire) -5.01%
07:00AM	Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4R Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases (GlobeNewswire)
Mar-12-24 04:01PM	Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $483 Million (GlobeNewswire)
Mar-07-24 06:49PM	Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering (GlobeNewswire)
Mar-05-24 10:53PM	APGE Stock Earnings: Apogee Therapeutics Beats EPS for Q4 2023 (InvestorPlace) +42.07% +12.46%
04:23PM	Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering (GlobeNewswire)
04:16PM	Apogee Catapults 42% After Eczema Drug Blows Expectations Out Of The Water (Investor's Business Daily)
07:35AM	IPO Stock Apogee Shifts Higher On Solid Phase 1 Outcome (Investor's Business Daily)
07:35AM	IPO Stock Apogee Rockets On Solid Phase 1 Outcome (Investor's Business Daily)
06:10AM	Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)

Apogee Therapeutics, Inc. operates as a biotechnology company. It offers treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications. The company was founded in 2022 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Feb 11 '26	Sale	63.35	20,000	1,266,953	1,172,987	Feb 13 08:00 PM
HENDERSON MICHAEL THOMAS	Officer	Feb 11 '26	Proposed Sale	64.00	60,000	3,840,000		Feb 11 10:42 AM
Dambkowski Carl	Chief Medical Officer	Feb 04 '26	Option Exercise	22.86	4,125	94,298	216,648	Feb 04 08:02 PM
Dambkowski Carl	Chief Medical Officer	Feb 04 '26	Sale	65.79	5,500	361,860	211,148	Feb 04 08:02 PM
Henderson Jane	Chief Financial Officer	Feb 02 '26	Sale	65.81	2,000	131,630	183,371	Feb 04 08:01 PM
Fairmount Funds Management LLC	Director	Jan 22 '26	Sale	76.30	1,750,000	133,525,000	298,647	Jan 22 08:07 PM
Fairmount Healthcare Fund II L	Director	Jan 22 '26	Proposed Sale	76.30	1,750,000	133,525,000		Jan 22 08:03 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Jan 14 '26	Sale	81.11	20,000	1,622,159	1,192,987	Jan 16 08:00 PM
Dambkowski Carl	Chief Medical Officer	Jan 07 '26	Option Exercise	22.86	14,025	320,612	231,223	Jan 09 08:00 PM
Dambkowski Carl	Chief Medical Officer	Jan 07 '26	Sale	77.84	18,700	1,455,613	212,523	Jan 09 08:00 PM
CARL DAMBKOWSKI	Officer	Jan 07 '26	Proposed Sale	78.25	35,200	2,754,400		Jan 07 04:27 PM
Henderson Jane	Chief Financial Officer	Jan 02 '26	Sale	74.86	6,000	449,146	187,371	Jan 06 08:00 PM
Henderson Jane	Chief Financial Officer	Jan 06 '26	Sale	80.00	2,000	160,000	185,371	Jan 06 08:00 PM
JANE HENDERSON	Officer	Jan 02 '26	Proposed Sale	75.48	12,000	905,760		Jan 02 04:31 PM
Henderson Jane	Chief Financial Officer	Dec 19 '25	Sale	80.00	1,500	120,000	193,371	Dec 23 08:00 PM
JANE HENDERSON	Officer	Dec 19 '25	Proposed Sale	77.35	1,500	116,025		Dec 19 04:24 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Dec 10 '25	Sale	75.38	20,000	1,507,657	1,212,987	Dec 12 08:00 PM
Dambkowski Carl	Chief Medical Officer	Dec 04 '25	Sale	75.00	10,900	817,500	271,108	Dec 05 08:03 PM
Henderson Jane	Chief Financial Officer	Dec 04 '25	Sale	75.00	1,500	112,500	194,871	Dec 05 08:02 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Dec 04 '25	Sale	75.01	40,000	3,000,400	1,232,987	Dec 05 08:00 PM
JANE HENDERSON	Officer	Dec 04 '25	Proposed Sale	74.55	1,500	111,825		Dec 04 04:43 PM
CARL DAMBKOWSKI	Officer	Dec 04 '25	Proposed Sale	74.55	10,900	812,595		Dec 04 04:41 PM
Henderson Jane	Chief Financial Officer	Nov 25 '25	Sale	70.00	1,500	105,000	196,371	Nov 28 08:00 PM
JANE HENDERSON	Officer	Nov 25 '25	Proposed Sale	67.85	1,500	101,775		Nov 25 04:28 PM
Henderson Jane	Chief Financial Officer	Nov 14 '25	Sale	65.00	2,000	130,000	197,871	Nov 14 08:00 PM
JANE HENDERSON	Officer	Nov 14 '25	Proposed Sale	62.97	2,000	125,940		Nov 14 04:31 PM
Henderson Jane	Chief Financial Officer	Nov 11 '25	Sale	60.00	1,000	60,000	199,871	Nov 13 08:37 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Nov 13 '25	Sale	63.01	20,000	1,260,236	1,272,987	Nov 13 08:24 PM
HENDERSON MICHAEL THOMAS	Officer	Nov 13 '25	Proposed Sale	66.98	100,000	6,697,800		Nov 13 10:33 AM
JANE HENDERSON	Officer	Nov 11 '25	Proposed Sale	56.77	1,000	56,770		Nov 12 07:03 AM
Dambkowski Carl	Chief Medical Officer	Nov 05 '25	Option Exercise	22.86	8,060	184,252	292,793	Nov 07 08:00 PM
Dambkowski Carl	Chief Medical Officer	Nov 05 '25	Sale	55.07	10,785	593,903	282,008	Nov 07 08:00 PM
CARL DAMBKOWSKI	Officer	Nov 05 '25	Proposed Sale	53.90	10,785	581,312		Nov 05 04:17 PM
Dambkowski Carl	Chief Medical Officer	Oct 01 '25	Option Exercise	22.86	2,385	54,521	289,843	Oct 03 08:00 PM
Dambkowski Carl	Chief Medical Officer	Oct 01 '25	Sale	39.80	5,110	203,378	284,733	Oct 03 08:00 PM
Dambkowski Carl	Chief Medical Officer	Sep 03 '25	Sale	37.87	2,725	103,198	233,548	Sep 05 08:00 PM
Dambkowski Carl	Chief Medical Officer	Aug 06 '25	Sale	37.78	2,725	102,950	236,273	Aug 08 08:00 PM
Dambkowski Carl	Chief Medical Officer	Jul 02 '25	Option Exercise	22.86	7,365	168,364	249,088	Jul 03 08:00 PM
Dambkowski Carl	Chief Medical Officer	Jul 02 '25	Sale	45.09	10,090	454,954	238,998	Jul 03 08:00 PM
CARL DAMBKOWSKI	Officer	Jul 02 '25	Proposed Sale	44.26	22,345	988,990		Jul 02 04:22 PM
Dambkowski Carl	Chief Medical Officer	Jun 04 '25	Sale	36.96	2,725	100,716	241,723	Jun 06 08:01 PM
Dambkowski Carl	Chief Medical Officer	May 07 '25	Sale	35.75	2,725	97,419	244,448	May 09 08:01 PM
Dambkowski Carl	Chief Medical Officer	Apr 02 '25	Sale	36.22	3,860	139,801	247,173	Apr 04 08:01 PM
CARL DAMBKOWSKI	Officer	Apr 02 '25	Proposed Sale	35.61	9,310	331,529		Apr 02 04:23 PM
Dambkowski Carl	Chief Medical Officer	Mar 05 '25	Sale	30.48	1,590	48,463	251,033	Mar 07 08:02 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Mar 05 '25	Sale	30.15	10,000	301,511	1,292,987	Mar 07 08:01 PM
HENDERSON MICHAEL THOMAS	Officer	Mar 05 '25	Proposed Sale	30.15	10,000	301,501		Mar 05 01:46 PM

Open in Screener

KURA

Kura Oncology Inc

Feb 13 • 04:00PM ET

8.31

+0.29 3.62 %

Healthcare • Biotechnology • USA • NASD

KURA Kura Oncology Inc daily Stock Chart

Peers: AGIO BLUE FATE ADAP EXEL IOVA KPTI KYNB

| Held by: VTI XBI IWM VXF AVUV IWN IBB VTWO SCHA VHT

Index	RUT	P/E	-	EPS (ttm)	-2.48	Insider Own	3.25%	Shs Outstand	87.02M	Perf Week	6.13%
Market Cap	723.12M	Forward P/E	-	EPS next Y	-3.25	Insider Trans	-4.80%	Shs Float	84.19M	Perf Month	-11.22%
Enterprise Value	192.93M	PEG	-	EPS next Q	-0.66	Inst Own	99.64%	Short Float	16.19%	Perf Quarter	-22.19%
Income	-216.88M	P/S	6.95	EPS this Y	-43.25%	Inst Trans	1.05%	Short Ratio	8.40	Perf Half Y	25.91%
Sales	104.03M	P/B	2.98	EPS next Y	-12.23%	ROA	-38.45%	Short Interest	13.63M	Perf YTD	-20.02%
Book/sh	2.79	P/C	1.32	EPS next 5Y	-6.73%	ROE	-65.10%	52W High	12.49 -33.47%	Perf Year	0.36%
Cash/sh	6.32	P/FCF	8.70	EPS past 3/5Y	-0.89% -6.05%	ROIC	-84.64%	52W Low	5.41 53.60%	Perf 3Y	-32.93%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	99.20%	Volatility	4.34% 4.86%	Perf 5Y	-75.90%
Dividend TTM	-	EV/Sales	1.85	EPS Y/Y TTM	-5.18%	Oper. Margin	-230.53%	ATR (14)	0.42	Perf 10Y	131.48%
Dividend Ex-Date	-	Quick Ratio	5.12	Sales Y/Y TTM	-	Profit Margin	-208.48%	RSI (14)	46.01	Recom	1.33
Dividend Gr. 3/5Y	- -	Current Ratio	5.12	EPS Q/Q	-35.14%	SMA20	1.03%	Beta	0.24	Target Price	32.45
Payout	-	Debt/Eq	0.08	Sales Q/Q	-	SMA50	-12.53%	Rel Volume	1.65	Prev Close	8.02
Employees	192	LT Debt/Eq	0.06	Earnings	Nov 04 BMO	SMA200	1.03%	Avg Volume	1.62M	Price	8.31
IPO	Sep 16, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	-16.44% 9.57%	Trades		Volume	2,670,615	Change	3.62%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-04-25	Initiated	Guggenheim	Neutral
Feb-06-25	Downgrade	BTIG Research	Buy → Neutral
Oct-24-24	Initiated	UBS	Buy	$27
Oct-14-24	Downgrade	Stifel	Buy → Hold	$26 → $19
Dec-22-23	Initiated	Mizuho	Buy	$26
Aug-11-23	Initiated	BofA Securities	Buy	$31
Jul-27-23	Initiated	Scotiabank	Sector Perform	$10.50
May-17-23	Initiated	BTIG Research	Buy	$31
Jan-31-23	Initiated	Stifel	Buy	$25
Jul-12-22	Initiated	Cantor Fitzgerald	Overweight	$30
Feb-15-22	Initiated	Jefferies	Buy	$35
May-05-21	Resumed	Credit Suisse	Outperform	$42
Apr-26-21	Resumed	Credit Suisse	Outperform	$42
Dec-07-20	Reiterated	H.C. Wainwright	Buy	$40 → $45
Dec-03-20	Initiated	Stifel	Buy	$45
Nov-05-20	Downgrade	Piper Sandler	Overweight → Neutral
Jul-07-20	Initiated	Credit Suisse	Outperform	$27
May-05-20	Initiated	Barclays	Overweight	$24
Jul-18-19	Initiated	Deutsche Bank	Buy	$28
Nov-09-18	Initiated	Piper Jaffray	Overweight

Show Previous Ratings

Feb-12-26 04:04PM	1 Under-$10 Stock Set to Surge as Much as 850% in 2026 (Barchart)
Feb-06-26 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.81%
Feb-02-26 09:36AM	Analyst Flags Kura Oncology, Inc. (KURA) for 2026 Milestones and Pipeline Expansion (Insider Monkey)
Jan-21-26 04:51AM	New Strong Sell Stocks for January 21st (Zacks)
Jan-14-26 09:16AM	Kura Oncology price target lowered to $20 from $25 at Leerink (TipRanks)
05:00PM	Loading…
Jan-11-26 05:00PM	Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones (GlobeNewswire)
Jan-05-26 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.69%
Dec-23-25 12:52AM	Jim Cramer Calls Kura Speculative But Says "It's One of the Stronger Ones I've Seen in a Very Long Time" (Insider Monkey)
Dec-21-25 10:26AM	Jim Cramer Discusses Kura Oncology as a Speculative Bet (Insider Monkey)
Dec-18-25 07:58PM	Lightning Round: Don't get involved in any 'year of magical investing' stock: Jim Cramer (CNBC TV)
Dec-15-25 11:10PM	Kura Oncology (KURA) Gains Momentum as Barclays Sees Significant Potential in Ziftomenib Approval (Insider Monkey)
Dec-08-25 10:30AM	Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML (GlobeNewswire)
Dec-04-25 12:20PM	Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points (PR Newswire)
Dec-03-25 08:32AM	Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia (GlobeNewswire) +7.55%
Dec-02-25 08:02AM	First U.S. Commercial Sale of KOMZIFTI Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin (GlobeNewswire)
05:16PM	Loading…
Nov-25-25 05:16PM	KOMZIFTI (ziftomenib) Added to National Comprehensive Cancer Network (NCCN) Guidelines for Acute Myeloid Leukemia (AML) (GlobeNewswire)
Nov-14-25 07:15AM	Kura and Kyowa Kirin secure FDA go-ahead for targeted leukaemia therapy (Pharmaceutical Technology)
06:06AM	Lundbeck sparks bidding war with Alkermes; Pfizer closes Metsera deal (BioPharma Dive)
Nov-13-25 10:51AM	Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia (GlobeNewswire)
Nov-12-25 04:05PM	Kura Oncology to Participate in Upcoming Investor Conference (GlobeNewswire)
Nov-07-25 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-04-25 04:03PM	Kura Oncology Inc (KURA) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Rising Expenses (GuruFocus.com)
07:45AM	Kura Oncology (KURA) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
06:50AM	Kura Oncology: Q3 Earnings Snapshot (Associated Press Finance)
06:31AM	Kura Oncology Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-03-25 04:02PM	Kura Oncology Receives Second $30 Million Development Milestone Payment in AML Menin Inhibitor Program With Kyowa Kirin (GlobeNewswire)
09:14AM	Kura Oncology and Kyowa Kirin Announce Presentations of Ziftomenib Ven/Aza Combination Data in Frontline and Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia at 2025 ASH Annual Meeting (GlobeNewswire)
07:50AM	What To Expect From Kura Oncology Inc (KURA) Q3 2025 Earnings (GuruFocus.com)
Oct-28-25 04:01PM	Kura Oncology to Report Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-24-25 07:02AM	Kura Oncology Receives $30 Million Development Milestone Payment in Ziftomenib AML Program with Kyowa Kirin (GlobeNewswire) +6.59%
03:23AM	Loading…
Oct-18-25 03:23AM	Kura Oncology Announces Preliminary Data from Its Farnesyl Transferase Inhibitor (FTI) Programs at the 2025 European Society for Medical Oncology (ESMO) Congress (GlobeNewswire)
Oct-03-25 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-01-25 07:01AM	Kura Oncology and Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition of NPM1 and FLT3 Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) (GlobeNewswire)
Sep-29-25 04:01PM	Kura Oncology and Kyowa Kirin Announce First Patient Dosed in Pivotal Phase 3 KOMET-017 Trial of Ziftomenib for Frontline Acute Myeloid Leukemia (AML) (GlobeNewswire)
Sep-25-25 05:18PM	Kura Oncology and Kyowa Kirin Announce Publication of Pivotal Ziftomenib Data in Relapsed/Refractory NPM1-Mutated AML in the Journal of Clinical Oncology (GlobeNewswire) +8.25%
Sep-24-25 07:30AM	Kura Oncology to Participate in Upcoming Investor Conference (GlobeNewswire)
Sep-16-25 04:01PM	Kura Oncology Highlights Preclinical Data Demonstrating Potential of Farnesyl Transferase Inhibitors to Overcome Drug Resistance in Combination with Key Targeted Therapies Across Multiple Tumor Types (GlobeNewswire)
Sep-08-25 12:30AM	LifeSci Capital Maintains Buy Rating on Kura Oncology (KURA) (Insider Monkey)
Sep-05-25 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-03-25 08:02AM	Kura Oncology to Host Virtual Investor and Analyst Events on Farnesyl Transferase Inhibitor Program (GlobeNewswire) +6.04%
Aug-28-25 07:30AM	Kura Oncology to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Aug-07-25 06:15PM	Kura Oncology (KURA) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -7.05%
05:16PM	Kura Oncology: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Kura Oncology Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-06-25 07:00AM	OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee (GlobeNewswire) -5.19%
Aug-04-25 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-31-25 07:30AM	Kura Oncology to Report Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-03-25 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-12-25 08:48AM	Is the Options Market Predicting a Spike in Kura Oncology Stock? (Zacks)
07:30AM	Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress (GlobeNewswire)
Jun-10-25 08:08PM	Lightning Round: 'Wait and see situation' with Papa John's, says Jim Cramer (CNBC TV)
Jun-06-25 11:52AM	KURA Stock Rises More Than 15% This Past Week: Here's Why (Zacks)
07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-02-25 06:00PM	Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting (GlobeNewswire) +10.72%
Jun-01-25 07:00PM	Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML (GlobeNewswire)
May-22-25 05:30PM	Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting (GlobeNewswire) -9.62%
May-20-25 07:30AM	Kura Oncology to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
May-14-25 10:00AM	Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress (GlobeNewswire)
May-06-25 07:30AM	Kura Oncology to Participate in Bank of America Securities Healthcare Conference (GlobeNewswire) -13.84%
May-02-25 10:51AM	Q1 2025 Kura Oncology Inc Earnings Call (Thomson Reuters StreetEvents)
07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
03:17AM	Kura Oncology Inc (KURA) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Rising Costs (GuruFocus.com)
May-01-25 08:48PM	Kura Oncology, Inc. (KURA) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:25PM	Kura Oncology (KURA) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:26PM	Kura Oncology: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Kura Oncology Reports First Quarter 2025 Financial Results (GlobeNewswire)
Apr-29-25 05:27AM	Kura doses first subjects in trial of ziftomenib for advanced GIST (Clinical Trials Arena)
Apr-28-25 07:30AM	Kura Oncology Announces First Patients Dosed in Phase 1 Combination Trial of Ziftomenib for the Treatment of Advanced GIST (GlobeNewswire)
Apr-24-25 07:30AM	Kura Oncology to Report First Quarter 2025 Financial Results (GlobeNewswire)
Apr-08-25 07:30AM	Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA (GlobeNewswire)
Apr-07-25 09:08AM	Syndax Pharmaceuticals: Down But Not Out (Seeking Alpha)
Apr-04-25 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-01-25 07:30AM	Kura Oncology to Participate in Stifel Targeted Oncology Forum (GlobeNewswire)
Mar-26-25 07:30AM	Kura Oncology Announces Preclinical Data for KO-2806 Selected for Oral Presentation at the 2025 AACR Annual Meeting (GlobeNewswire)
Mar-07-25 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-27-25 11:19AM	Q4 2024 Kura Oncology Inc Earnings Call (Thomson Reuters StreetEvents)
02:24AM	Kura Oncology Inc (KURA) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial Growth (GuruFocus.com)
Feb-26-25 05:35PM	Kura Oncology (KURA) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:42PM	Kura Oncology: Q4 Earnings Snapshot (Associated Press Finance)
04:03PM	Kura Oncology Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-25-25 07:30AM	Kura Oncology to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Feb-19-25 07:30AM	Kura Oncology to Report Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-07-25 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-05-25 04:01PM	Kura Oncology and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial Designs (GlobeNewswire)
Jan-06-25 04:30PM	Kura Oncology Announces Senior Executive Promotions (GlobeNewswire)
Dec-09-24 07:00AM	Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting (GlobeNewswire)
Dec-04-24 01:25PM	Why Is Kura Oncology, Inc. (KURA) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? (Insider Monkey)
Dec-02-24 07:30AM	Kura Oncology to Host Virtual Investor Event on December 9, 2024 (GlobeNewswire)
Nov-25-24 07:30AM	Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit (GlobeNewswire)
Nov-23-24 10:42AM	Kura Oncology, Inc. (KURA): Among the Most Promising Cancer Stocks According to Hedge Funds (Insider Monkey)
Nov-22-24 05:30AM	Halozyme drops Evotec buyout bid; Patient dies in Neurogene trial (BioPharma Dive) +7.36%
Nov-21-24 04:15PM	Kura Crashes 37% After $1.53 Billion Deal Slams The Door On A Takeover (Investor's Business Daily) -36.77%
09:05AM	Kura Oncology Slams The Door On Its Takeover Narrative, And Shares Collapse 26% (Investor's Business Daily)
06:37AM	Kura Oncology partners Kyowa Kirin to advance AML treatment (Pharmaceutical Technology)
Nov-20-24 05:00PM	Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias (PR Newswire)
Nov-08-24 04:01PM	Kura Oncology Inc (KURA) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising Expenses (GuruFocus.com)
Nov-07-24 05:15PM	Kura Oncology: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Kura Oncology Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-05-24 09:09AM	Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting (GlobeNewswire)
Oct-31-24 07:30AM	Kura Oncology to Report Third Quarter 2024 Financial Results (GlobeNewswire)

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Powl Brian T.	Chief Commercial Officer	Jan 27 '26	Sale	8.46	6,414	54,266	183,275	Jan 27 09:35 PM
FORD KATHLEEN	Chief Operating Officer	Jan 27 '26	Sale	8.46	1,813	15,339	153,560	Jan 27 09:35 PM
Leoni Mollie	Chief Medical Officer	Jan 27 '26	Sale	8.46	8,180	69,209	267,274	Jan 27 09:35 PM
DOYLE THOMAS JAMES	SVP, Finance & Accounting	Jan 27 '26	Sale	8.46	7,142	60,426	145,167	Jan 27 09:35 PM
Burrows Francis	Chief Scientific Officer	Jan 27 '26	Sale	8.46	1,311	11,092	32,424	Jan 27 09:35 PM
Bair Teresa Brophy	Chief Legal Officer	Jan 27 '26	Sale	8.46	11,208	94,828	226,931	Jan 27 09:35 PM
BAIR TERESA BROPHY	Officer	Jan 27 '26	Proposed Sale	8.47	11,208	94,932		Jan 27 09:30 PM
POWL BRIAN T	Officer	Jan 27 '26	Proposed Sale	8.47	6,414	54,327		Jan 27 09:30 PM
FORD KATHLEEN	Officer	Jan 27 '26	Proposed Sale	8.47	1,813	15,356		Jan 27 09:30 PM
LEONI MOLLIE	Officer	Jan 27 '26	Proposed Sale	8.47	8,180	69,285		Jan 27 09:30 PM
BURROWS FRANCIS	Officer	Jan 27 '26	Proposed Sale	8.47	1,311	11,104		Jan 27 09:30 PM
DOYLE THOMAS JAMES	Officer	Jan 27 '26	Proposed Sale	8.47	7,142	60,493		Jan 27 09:30 PM
Burrows Francis	Chief Scientific Officer	Dec 18 '25	Option Exercise	4.80	35,000	168,000	57,461	Dec 19 04:30 PM
Burrows Francis	Chief Scientific Officer	Dec 18 '25	Sale	9.78	23,726	231,931	33,735	Dec 19 04:30 PM
FRANCIS J BURROWS	Officer	Dec 18 '25	Proposed Sale	9.78	23,726	231,934		Dec 18 04:07 PM
Hasnain Faheem	Director	Dec 09 '25	Option Exercise	3.12	10,000	31,200	33,983	Dec 10 04:05 PM
Hasnain Faheem	Director	Dec 09 '25	Sale	10.98	10,000	109,764	23,983	Dec 10 04:05 PM
FAHEEM HASNAIN	Director	Dec 09 '25	Proposed Sale	11.64	10,000	116,400		Dec 09 04:23 PM
Bair Teresa Brophy	Chief Legal Officer	Nov 14 '25	Sale	11.18	8,804	98,401	188,139	Nov 14 08:00 PM
Powl Brian T.	Chief Commercial Officer	Nov 14 '25	Sale	11.18	8,887	99,329	139,689	Nov 14 08:00 PM
Leoni Mollie	Chief Medical Officer	Nov 14 '25	Sale	11.18	15,485	173,074	225,454	Nov 14 08:00 PM
DOYLE THOMAS JAMES	SVP, Finance & Accounting	Nov 14 '25	Sale	11.18	4,539	50,732	130,257	Nov 14 08:00 PM
FORD KATHLEEN	Officer	Nov 14 '25	Proposed Sale	10.68	6,902	73,713		Nov 14 08:00 PM
DOYLE THOMAS JAMES	Officer	Nov 14 '25	Proposed Sale	10.68	4,539	48,477		Nov 14 08:00 PM
FORD KATHLEEN	Chief Operating Officer	Nov 14 '25	Sale	11.18	6,902	77,143	105,373	Nov 14 08:00 PM
LEONI MOLLIE	Officer	Nov 14 '25	Proposed Sale	10.68	15,485	165,380		Nov 14 08:00 PM
POWL BRIAN T	Officer	Nov 14 '25	Proposed Sale	10.68	8,887	94,913		Nov 14 08:00 PM
BAIR TERESA BROPHY	Officer	Nov 14 '25	Proposed Sale	10.68	8,804	94,027		Nov 14 08:00 PM
WILSON TROY EDWARD	Officer	Sep 29 '25	Proposed Sale	9.05	36,615	331,366		Sep 29 07:50 PM
LEONI MOLLIE	Officer	Sep 29 '25	Proposed Sale	9.05	12,314	111,442		Sep 29 07:50 PM
POWL BRIAN T	Officer	Sep 29 '25	Proposed Sale	9.05	8,891	80,464		Sep 29 07:50 PM
BAIR TERESA BROPHY	Officer	Sep 29 '25	Proposed Sale	9.05	8,805	79,685		Sep 29 07:50 PM
DOYLE THOMAS JAMES	Officer	Sep 29 '25	Proposed Sale	9.05	4,541	41,096		Sep 29 07:50 PM
FORD KATHLEEN	Officer	Sep 29 '25	Proposed Sale	9.05	6,892	62,373		Sep 29 07:50 PM
Powl Brian T.	Chief Commercial Officer	Sep 29 '25	Sale	8.94	8,891	79,505	99,676	Sep 29 07:30 PM
Bair Teresa Brophy	Chief Legal Officer	Sep 29 '25	Sale	8.94	8,805	78,736	148,043	Sep 29 07:30 PM
FORD KATHLEEN	Chief Operating Officer	Sep 29 '25	Sale	8.94	6,892	61,630	63,375	Sep 29 07:30 PM
Leoni Mollie	Chief Medical Officer	Sep 29 '25	Sale	8.94	12,314	110,114	158,439	Sep 29 07:30 PM
WILSON TROY EDWARD	President and CEO	Sep 29 '25	Sale	8.94	36,615	327,419	246,853	Sep 29 07:30 PM
DOYLE THOMAS JAMES	SVP, Finance & Accounting	Sep 29 '25	Sale	8.94	4,541	40,607	109,829	Sep 29 07:30 PM
WILSON TROY EDWARD	President & CEO	Sep 08 '25	Buy	8.20	50,000	410,145	100,968	Sep 09 04:28 PM
WILSON TROY EDWARD	President and CEO	Aug 12 '25	Buy	5.85	36,506	213,578	37,474	Aug 14 04:05 PM
WILSON TROY EDWARD	President and CEO	Aug 13 '25	Buy	6.64	13,494	89,623	50,968	Aug 14 04:05 PM
Bair Teresa Brophy	Chief Legal Officer	May 19 '25	Sale	5.96	1,559	9,292	107,948	May 19 06:30 PM
FORD KATHLEEN	Chief Operating Officer	May 19 '25	Sale	6.28	1,558	9,777	21,367	May 19 06:30 PM
FORD KATHLEEN	Officer	May 19 '25	Proposed Sale	5.96	1,558	9,286		May 19 04:06 PM
Hasnain Faheem	Director	Mar 21 '25	Option Exercise	6.32	22,682	143,350	46,665	Mar 24 04:33 PM
Hasnain Faheem	Director	Mar 21 '25	Sale	8.00	22,682	181,456	23,983	Mar 24 04:33 PM
FAHEEM HASNAIN	Director	Mar 21 '25	Proposed Sale	7.85	30,000	235,500		Mar 21 04:21 PM

DNTH

Dianthus Therapeutics Inc

RVMD

Revolution Medicines Inc

CRWV

CoreWeave Inc

APGE

Apogee Therapeutics Inc

KURA

Kura Oncology Inc

Upgrade your FINVIZ experience